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ABSTRACT 
Introduction: Gastro-oesophageal reflux disease (GORD) affects 40% of Western 
populations. Many symptoms persist despite the resolution of inflammation or acid 
exposure. In these patients, visceral pain hypersensitivity (VPH), modulated 
peripherally and centrally, is believed to be important.  
Study 1: Full thickness human oesophageal samples were collected from 10 patients 
undergoing oesophagectomy. Using immunohistochemistry, the samples were stained 
with PGP 9.5, synapthophysin, TRPV1, TRPV4 and ASIC3. Within healthy areas of 
the human oesophagus, immunoreactive nerve fibres and ganglia were identified in 
the sub-epithelium and myenteric plexus. Within the epithelium, nerve endings were 
absent; however, ASIC3 was reliably identified in epitheliocytes. 
Study 2: Oesophageal biopsy samples from 36 individuals were collected during upper 
GI endoscopy; erosive oesophagitis, non-erosive reflux disease and controls. 
Symptoms were profiled using symptom severity scores, adapted from a validated 
questionnaire. Oesophageal mucosal biopsies were taken 3-5 cm above the lower 
oesophageal sphincter. Specific features of oesophageal mucosal epithelial ASIC3 
were identified by immunohistochemistry, which were associated positively with an 
increase in symptom severity.  
Study 3: Oesophageal VPH can be induced in healthy volunteers using an established 
model of acid infusion. In total, 85 retrospective infusions from 57 volunteers were 
studied, and VPH was present in 70%. The model was shown to be safe and 
reproducible, but reliability of the model for drug studies was only valid provided 
control measures were observed. 
Study 4: Pregabalin is a centrally acting calcium channel blocker currently used for 
somatic neuropathic pain and partial seizures. Using the model described in study 3, a 
prospective, double-blinded, cross-over, placebo-controlled study in 15 healthy 
volunteers was performed. After an initial screening visit, the volunteers were 
randomised to either pregabalin or placebo. Pregabalin prevented or attenuated VPH 
at 30 and 90 minutes after acid sensitisation. 
Conclusion: The evidence for central sensitisation was further consolidated with the 
pregabalin study and peripheral sensitisation by the ASIC3 study. The evidence is 
important in the detection of predominant mechanisms underlying the symptoms of 
patients with GORD for both cohort development and targeted treatment.  
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INTRODUCTION: ANATOMY AND PHYSIOLOGY 
OF THE OESOPHAGUS, THE PERCEPTION OF 
GASTRO-OESOPHAGEAL REFLUX AND THE 
ROLE OF VISCERAL PAIN HYPERSENSITIVITY  
 
1.1 THE HUMAN OESOPHAGUS 
The oesophagus is part of the gastro-intestinal tract, connecting the oral cavity to the 
stomach. Food, once chewed, tasted, lubricated in the mouth and confirmed as safe by 
the brain for ingestion, is transported into the stomach via the oesophagus. Within this 
passage, food is propelled into the stomach for digestion and disinfection by highly 
acidic gastric secretion. The length and tone of this muscular tube also allow gastric 
content to remain in place and not be easily regurgitated, even 
during vigorous physical activities. This allows nutrition to 
remain within the body and prevents corrosive digestive juices 
from contaminating the oesophagus itself as well as the mouth, 
teeth and vocal cords. Swallowing solids can even take place 
when one is upside down or in outer space, with peristalsis 
alone without the help of gravitational force. Gastric content 
can also be expelled retrogradely against gravity in vomiting 
and reflux. Although physically it appears to be just a simple 
muscular tube connecting the mouth and stomach, muscular 
composition and innervation are such that this tube can sense a 
multitude of stimuli, propel a food bolus inwards and outwards 
and form areas of high tone (sphincters) which contract and 
relax appropriately. All of these functions are only possible due 
to the extensive nerve supply, receptors and musculature arrangements within this 
complex organ. Many of the physiological roles of the oesophagus can be altered in 
pathological states, and to understand how these are altered in disease states. 
 
 
 
1 
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1.2 ANATOMICAL CONSIDERATION 
The oesophagus, although a single tube, can be divided into upper, middle and lower 
parts. This distinction is not just physical, but has different embryological bases which 
determine the anatomy of the organ including muscular composition, nerve 
innervation, vascular supply and drainage. The embryological origin of the upper 
oesophagus is from branchial arches 4 and 5
1
, which form mainly the striated 
muscular components of the upper and middle oesophagus, while the lower 
oesophagus originates from mesenchyme of the somites
1
, which forms the smooth 
muscle layers of the middle and lower oesophagus. 
 
1.2.1 Muscle layers 
The oesophagus measures 18-25 cm in length and is mainly a muscular organ
1
. The 
muscular composition of the oesophagus is mainly striated in the upper oesophagus, 
and as it progresses to the lower oesophagus, it becomes more mixed with smooth 
muscle. By the lower third of the oesophagus, it is mainly smooth muscle, composed 
of the outer longitudinal muscle and inner circular layer
2
. The longitudinal muscle is 
arranged in fascicular columns, which are more distinct in the upper oesophagus and 
they merge into a single sheet of muscle towards the distal oesophagus
1
. The circular 
muscle is arranged as a set of concentric circles and provides peristaltic contractions. 
Accessory bands of muscles connect the oesophagus to adjacent structures. 
 
The two oesophageal sphincters – the upper oesophageal sphincter (UOS) and lower 
oesophageal sphincter (LOS) are muscular sphincters. The oesophagus maintains the 
separation of between different organs; proximally, the oropharynx and distally, the 
stomach. The UOS is mainly a functional sphincter, an area packed with highly 
sensitive nerves and reflexes that initiate swallowing and regurgitation. The LOS, on 
the other hand, is both a functional as well as an anatomical sphincter, and acts as a 
high pressure zone before the oesophagus forms the stomach. The high tone is 
maintained by constant smooth muscle contraction controlled by nervous plexi and 
neuro-hormonal factors. In addition, the anatomy of the LOS represents an area of 
thickened musculature, corresponding to the diaphragmatic ring, which enters the 
abdomen at an angle. These mechanisms form the LOS and prevent the reflux of 
gastric contents as well as allowing the entry of food bolus into the stomach when 
necessary.  
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1.2.2 Layers of the oesophagus 
Although essentially a muscular tube, the oesophagus is organised into distinct layers, 
which allow for movements between the layers that are optimum for a dynamic tube. 
Within these layers, blood vessels, nerves complexes, receptors and connective tissues 
exist. The luminal surface of the oesophagus is lined by non-stratified stratified 
squamous epithelium
2
, which is adapted to withstand abrasions. The epithelium is rich 
in receptors and sensitive nerves endings
3
 that respond to a range of stimuli; therefore, 
an intact epithelium is essential in normal oesophageal sensation. The range of sensory 
biomarkers and proteins important in oesophageal sensation is discussed further in 
section 1.1.2.1: Peripheral sensitisation. Below the epithelium are the lamina propria 
and muscularis mucosae
4
. All three layers constitute the mucosal layer
4
. The 
submucose is mainly connective tissue and contains the sub-mucosal nerve plexus. 
The third layer is the muscular coat, consisting of inner circular and outer longitudinal 
muscles
1
. The anterior aspect of the oesophagus is protected by the serosa.  
 
 
 
Figure 1.1: Different layers of the oesophagus including retroperitoneal and 
intraperitoneal aspects of the oesophagus. (Anaesthesia UK: training site of Royal 
College of Anaesthetics, UK) 
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1.2.3. Arterial supply 
The arterial supply to the oesophagus is based on the division of its upper, middle and 
lower parts. Arterial supply to the upper oesophagus derives from the branches of the 
inferior thyroid artery, which originates from the subclavian artery
2
. The middle 
oesophagus is supplied by terminal branches of the bronchial arteries, while the lower 
oesophagus derives its blood supply from the left gastric artery
2
. However, the 
oesophagus is highly vascularised, with an extensive anastamotic network and 
collaterals. There is considerable overlap between territories. 
.  
1.2.4 Venous drainage 
The venous drainage of the oesophagus is less well demarcated by the three areas. The 
upper and middle parts of the oesophagus drain into the systemic venous circulation 
via the azygous system
2
. The lower third empties into the left gastric vein, which is 
part of the hepatic portal system
2
. This area of anastamoses between the systemic and 
portal system is where oesophageal varices arise from portal hypertension, in turn 
obstructing venous drainage from the distal oesophagus that drains into the portal 
vein. This causes pressure build up in the venous drainage of the distal oesophagus. 
 
1.2.5 Innervation and control 
 
1.2.5.1 Intrinsic nerve supply 
Based on histological layers, as suggested by the existence of double muscular 
complexes (one more superficially at the muscularis mucosae, and the other deeper 
muscle complex with the two layers of muscle – inner circular and outer longitudinal), 
it is hardly surprising that there are also two separate plexi within the wall of the 
oesophagus. Associated within the submucosal layer is Meissner’s plexus, which 
innervates the muscularis mucosae and secretory glands. Within the deeper muscular 
layer, between the longitudinal and circular muscle layers, is the myenteric 
Auerbach’s plexus, which controls contractions of the circular and longitudinal layers. 
The myenteric plexus also exists in the striated muscle of the upper oesophagus, 
although its function there is less clear. Together, the submucosal (Meissner’s) and 
myenteric (Auerbach’s) plexi form the intrinsic innervation of the oesophagus. A 
network of fibres is believed to connect the two plexi
1
. The coordination of 
spontaneous peristalsis by the smooth muscle is controlled by the intrinsic system, 
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which is independent from extrinsic control.  
 
1.2.5.2 Extrinsic nerve supply 
 
A) Motor innervation 
The main motor supply of the oesophagus is the vagus nerve, which supplies the upper 
and lower oesophagus. Branches supplying the upper oesophageal muscles and upper 
oesophageal sphincter come from the nucleus ambiguus, whereas the vagal efferents 
for the distal oesophagus and lower oesophageal sphincter originate from the dorsal 
motor neuron of the vagus nerve
1
. Although the vagus controls most of the motor 
function of the oesophagus, it is mainly a sensory nerve, with up to 85% of its nerve 
fibres being sensory
5
. This is discussed further below. 
 
B) Sensory innervation 
The sensory nerves of the oesophagus are less well studied to date compared to motor 
nerves. The sharpness of sensation in the viscera is also much less discrete compared 
to somatic sensation. However, sensory modalities that exist within the oesophagus 
are quite wide ranging including thermo-, chemo- and mechano-sensations. Sensory 
innervation can be divided into two systems, namely vagal afferents, which are mainly 
parasympathetic, and spinal afferents, which are predominantly sympathetic
6
. These 
systems share some similar activation pathways
7
 and interact accordingly
6
. For 
example, the vagus system, had also been shown to reduce hyperalgesia by reducing 
the release of epinephrine from adrenals
8
, as well as reducing sympathetically 
controlled neurogenic inflammation
9
. 
 
Vagus afferents 
Vagal fibres are mainly unmylelinated C-fibres that have their cell bodies in the 
nodose ganglia before projecting into the nucleus solitary tract (NST). From the NST, 
these fibres form synapses with second-order neurons and project to the brainstem, 
hypothalamus, amygdala and cerebral cortex
5 10
. Vagal afferents are traditionally 
thought to mediate physiological sensations such as satiety and nausea
11
. However, 
related to its physiological motor function, the vagus nerve is also believed to be 
sensitive to mechanosensation
11
. Vagal afferents have receptors in the mucosa, which 
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respond to mucosal fine stroking as well as tension receptors in the oesophageal wall 
that are responsive to distension
12
. Smooth peristalsis requires both effective sensation 
of distension as well as contractions. Vagal afferents are also enriched with receptors 
responsive to polymodal intra-luminal stimuli
8
 including osmo
13
, chemo
14
 and 
thermo
15
 sensations. 
 
Spinal afferents 
The current understanding is that mucosal nerve endings, located in the lamina propria 
of the mucosa, sense intra-luminal stimuli
3
. These nerve endings are mainly spinal 
afferents whose cell bodies are found in dorsal root ganglia. From the spinal cord, they 
travel into the thalamus and primary sensory cortical areas. The distribution of nerve 
endings is thought to vary according to stimuli. Acid sensing nerve endings are 
believed to be superficial in the epithelium, whereas nerve endings deeper in the 
muscle and serosa are believed to be important for mechano sensation. Currently, 
many of the roles of these nerve endings can merely be speculated upon based on their 
anatomical locations. Systematic studies of oesophageal sensation have been difficult 
because the reporting of sensation is subjective and requires effective communication 
to the researcher. Animal studies have limited contribution and human studies are 
limited by difficulty in obtaining full thickness samples. As a result, many of the 
studies that have researched oesophageal sensation are controversial and inconclusive.  
 
1.2.5.3 Autonomic Nervous System 
As discussed above in motor supply, the predominantly parasympathetic
13
 vagus 
provides motor innervation to the muscular layers as well as secretory function to the 
mucosal glands. The origins of PNS for the vagus are the nucleus ambiguous and 
dorsal motor nucleus. Sympathetic innervation of the oesophagus originates mainly 
from the thoracic sympathetic chain (T1-10), with the first thoracic ganglion 
frequently joined to the cervical ganglion to form the stellate ganglion
2
. The 
sympathetic system regulates vascular smooth muscle tone, and to a lesser extent the 
parasympathetic system, oesophageal contractile and secretory functions. Sympathetic 
activation had been traditionally believed to increase LOS tone and cause 
contraction
16
 via the adrenergic system
17
; however, a cat study did not show the 
benefit of sympathetic modulation in influencing LOS function in combination with 
baclofen 
18
. 
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1.2.5.4 Central nervous system  
The two main areas for oesophageal sensation within the brain, including pain 
processing, are the thalamus and cerebral cortex. The thalamus, located in the 
diencephalon at the dorsal end of the brainstem, forms the central core of the brain. It 
is an important centre for relaying and integrating important sensory and motor 
messages from the periphery to the cortical areas. It also integrates factors such as 
consciousness, attention, memory and emotions. The cortical areas of oesophageal 
sensation are the cingulate, insular, sensory, parietal occipital, and prefrontal regions 
based on human studies 
19-21
. The significance of each area and cortical activity in 
relation to pain/acid sensation is discussed further in section 1.5.3.3: Cortical 
mechanisms. 
 
Since the motor function of the oesophagus is mainly involuntary, much of the known 
information of the role that the central nervous system plays in its function pertains to 
sensation. However, there is limited evidence of motor representation of oesophagus 
in the cortex in swallowing studies. A sophisticated human study using transcranial 
magnetic stimulation and magnetic resonance imaging by Hamdy, et al. showed that 
swallowing musculature is discreetly and somatotopically represented in the motor 
and pre-motor cortex of both hemispheres asymmetrically – and not influenced by the 
dominant handedness. The loci for myolohyoid, pharynx and oesophagus were 
discreet, with the oesophageal locus predominantly in the pre-motor cortex
22
. Cortical 
swallowing motor pathways from each hemisphere interact and their excitability is 
modulated by sensory input
23
. For example, stimulation of afferent branches of the 
cranial trigeminal and vagus nerves have been shown to facilitate cortical swallowing 
pathways in the brainstem
24
, which will be discussed further below. 
 
 
1.3 PHYSIOLOGY AND FUNCTION 
 
1.3.1 Swallowing 
Swallowing is functionally divided into three stages, namely oral, pharyngeal and 
oesophageal reflecting the anatomical structures involved
23
. Functional activation of 
  Y. C. Chua 
 
___________________________________________________________________________________ 
 
 35 
these centres is divided further into two – cortical centres to initiate and modulate 
volitional swallowing
25 26
, whilst the brainstem swallowing centre coordinates the 
sequence of reflex events in swallowing via cranial nerves (trigeminal, 
glossopharyngeal, vagus and hypoglossal)
26
 to the protect airway and simultaneously 
generate coordinated muscle contraction and relaxation, leading to oesophageal 
peristalsis
23
. 
 
Peristalsis in swallowing is created by coordinated contraction and relaxation of the 
smooth muscle complex, all of which is coordinated by the cortex and swallowing 
centre. These contractions are also coordinated by local reflexes via the intrinsic plexi. 
The external innervation of the oesophagus, sensory, motor and ANS modulates 
peristalsis. The primary function of the oesophagus is to allow the ingestion of food 
and nutrients necessary for metabolism and growth in humans.  
 
1.3.2 Prevention of Reflux 
Related to the main function of swallowing and entry of food into the stomach, the 
lower oesophageal sphincter (LOS) also functions to prevent the reflux of gastric 
contents into the oesophagus. The LOS, as described above, is a muscular as well as a 
functional sphincter dependent on the maintenance of muscular tone and its angle. 
Any inability of the LOS to relax and contract appropriately would result in diseased 
states. Dysphagia and achalasia occur when the oesophagus and LOS fail to relax in a 
coordinated way to allow the entry of food. Gastro-oesophageal reflux disease 
(GORD) is associated with the spillage of gastric contents into the oesophagus. Many 
factors normally contribute to the prevention of this backflow from happening, and in 
GORD one or more of these mechanisms may fail (discussed below in: Pathogenesis 
of GORD). 
 
 
1.4 GASTRO-OESOPHAGEAL REFLUX DISEASE 
Gastro-oesophageal reflux disease (GORD) is a common condition. Estimates suggest 
that between 20 and 44% of Western populations having symptoms of GORD at least 
once a month and 20% weekly
5 6
. GORD can be divided broadly into erosive 
oesophagitis (EO) and non-erosive reflux disease (NERD). EO sufferers demonstrate 
signs of inflammation or superficial ulcers on endoscopy, but NERD patients do not 
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have any abnormalities. Of all the patients with GORD, it is estimated that between 50 
and 70% have NERD
7 8
.  
 
1.4.1 Pathogenesis of acid reflux 
 
1.4.2.1 Anatomical defects 
Increased oesophageal acid exposure in GORD has several potential causes, some 
related primarily to physiological dysfunction and others to anatomic defects of the 
gastro-oesophageal junction, such as in a hiatus hernia. The importance of hiatus 
hernias in the pathogenesis of GORD is obscured by imprecise definitions that have 
led to wide variations in estimates of their prevalence across populations. Diagnosis 
could be made based on radiological or endoscopic methods. A hiatus hernia occurs 
when the stomach protrudes through the diaphragm into the chest cavity. In so doing, 
the LOS is compromised, and the reflux of gastric contents (including acid) into the 
oesophagus can occur easily. From an epidemiological standpoint, hiatus hernias and 
GORD share similarities in that both become more common with age and obesity. 
However, since the LOS is also functional sphincter, GORD and acid reflux could 
occur without the presence of anatomical distortion like a hiatus hernia. 
 
1.4.2.2 Transient lower oesophageal sphincter relaxations (TLOSRs) 
The LOS contracts and relaxes appropriately to allow the inward passage of food into 
the stomach for digestion, and prevents the reflux of gastric content. Even in the 
presence of normal anatomy, inappropriate and uncoordinated relaxation of the LOS 
can cause reflux. This phenomenon is referred to as ‘transient lower oesophageal 
sphincter relaxations’ (TLOSRs). In a study in human volunteers, gastro-oesophageal 
reflux was shown to be unrelated to low steady-state basal LOS pressure, but rather 
occurred during inappropriate transient relaxations
27
. TLOSRs mostly tend to occur 
after eating due to the distension of the proximal stomach
28 29
, although they can occur 
spontaneously, too. It is thought to be a vagally mediated reflex from gastric mechano-
distension
28 30
. A study in humans after fundoplication showed that TLOSRs were 
reduced, although gastric accommodation was not altered – indicating that the 
receptive field for TLOSRs was located within the region affected by fundoplication; 
i.e. proximal stomach
29
 close to the oesophagus.  
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1.4.2.3 Motility and gastric emptying 
Poor oesophageal clearance and high intra-gastric pressure have been implicated in 
increasing acid reflux, whilst ineffective oesophageal motility has been implicated in 
poor oesophageal acid clearance, especially in the supine position
31
, together with 
reduced salivation
32. These factors reduce the ‘push’ or forward factors for 
oesophageal clearance and the neutralisation of acid. Increased intra-gastric pressure 
or motility, on the other hand, prevent clearance and can therefore contribute 
backward pressure and increased reflux
27
. Cisapride, a prokinetic agent, has been 
shown in combination with Ranitidine to reduce the number and duration of reflux 
episodes in patients with oesophagitis
33
. In the same study, cisapride was also shown 
to enhance oesophageal clearance
33
. Although many of these factors may be relevant 
to nocturnal GORD symptoms while in the supine position, ineffective persistaltic 
clearance and TLOSRs were found to be most important and relevant
27
 . 
 
1.4.2.4 Sustained oesophageal contractions 
Contractions of the longitudinal smooth muscle could occur spontaneously. These 
contractions are termed ‘sustained oesophageal/esophageal contractions’, more 
commonly known as SECs, which have been demonstrated to increase the wall 
thickness of the oesophagus
34
, which corresponds to heartburn symptoms
35 36
. In most 
patients (70%), SECs precede heartburn symptoms and are reproduced in 75% of 
Bernstein positive subjects
35
. While this provides an explanation for symptoms 
associated with acid exposure, the mechanisms for symptoms remain speculative. 
Contractions may cause acid reflux or SECs may trigger pain by causing transient 
ischaemia or neuronal activation.  
 
1.4.2 GORD symptoms 
GORD symptoms can be very wide ranging, from the classic feeling of heartburn
37
, 
indigestion and bloating to some very atypical presentations such as recurrent 
aspiration pneumonia
38
 and tooth decay
39
. Heartburn is typically described as burning 
chest discomfort extending from the upper abdomen to the chest and sometimes to the 
jaw. As the name suggests, this symptom is often confused with cardiac chest pain. 
Regurgitation is another common symptom of GORD, often associated with an acidic 
taste in the mouth. When heartburn or acid regurgitation dominate the patient’s 
symptoms, they have very high specificity but low sensitivity for GORD
37
. Other 
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common symptoms include feelings of sickness, bloating and an acidic taste in the 
mouth. 
 
 
1.5 VISCERAL PAIN HYPERSENSITIVITY IN OESOPHAGUS 
 
1.5.1 Role of visceral pain hypersensitivity in GORD  
In patients with EO, inflammation and/or erosions are assumed to cause the 
symptoms. However, NERD patients exhibit evidence of abnormal acid exposure 
times but no evidence of erosions. In these patients, increased sensitivity to acid is 
suggested by a significantly shorter lag time and higher pain score to acid infusion in 
comparison to healthy volunteers
40, Barrett’s patients and even EO. This also 
demonstrates that sensitivity to acid in fact is not dependent on erosive changes in the 
oesophageal mucosa. Furthermore, abnormal responses to the Bernstein test
41
 have 
been demonstrated in the majority of patients who use antacids and report chronic 
heartburn but have normal acid contact time
41
. This suggests that these patients are 
hypersensitive to the physiological reflux of acid. In addition, some patients have all 
the hallmarks and symptoms of GORD, but do not have objective evidence of 
abnormal acid exposure. These patients are classified as having functional heartburn 
(FH). Symptoms in FH are considered to be due to excessive sensitivity to 
physiological amounts of acid. 
 
In both the presence and absence of inflammation, acid is the main triggering factor in 
symptom generation in GORD. The corrosive effects of acid can be sensed by sensory 
nerves and receptors in the oesophageal epithelium (Chapter 2). Damage and 
inflammation will also facilitate dilation of the intercellular spaces and exposure to 
acid of the sub-epithelial nerves, leading to further symptom generation. Repeated 
exposure of these nerves could lead to their sensitisation so that symptoms could occur 
with even minor or physiological reflux episodes; a phenomenon described as visceral 
pain hypersensitivity (VPH). The following sections will deal with peripheral and 
central VPH mechanisms. 
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1.5.2 Peripheral mechanisms 
Gastrointestinal pain is mediated by spinal visceral afferent fibres, with a probable 
important contribution from vagal afferent fibres.
42
 When activated, mechanoreceptors 
and chemo-sensitive receptors (resident in mesentery, serosa and submucosa) 
depolarise A- and C-fibres. The ability to transduce noxious mechanical, chemical or 
thermal stimuli into generator currents able to depolarise such fibres is a property of 
transducer channels such as transient receptor potential (TRP) channels. TRPV1, 
TRPV4 and TRPA1 channels have been shown to have a role in GI nociception, as 
have acid-sensing ion channels (ASICs) and P2x purinoceptors
43
. In the presence of 
tissue inflammation or injury, there is an up-regulation of pain transmission. The 
ability to enhance pain transmission to the brain in these situations is important, as 
heightened bodily awareness can alter behaviour, which in turn aids in the protection 
of injured sites and the promotion of healing. Research in somatic pain has suggested 
that both peripheral and central mechanisms can increase nociceptive transmission 
following inflammation or injury to tissues. Peripheral mechanisms include peripheral 
sensitisation (PS), which is an inflammatory mediator-induced facilitation of 
nociceptor activity in peripheral tissues. Peripheral sensitisation causes pain 
hypersensitivity at the site of injury or inflammation, also known as primary 
hyperalgesia. Here, inflammatory products including bradykinin, histamine, 5HT, 
prostanoids, proteases and cytokines permit nociceptor firing at reduced thresholds. 
 
Receptors that may be involved in PS are described below: 
 TRPV channels – Transient receptor potential vanilloid receptors, or vanilloid 
receptors (VR). This is a group big of receptors. They are cation-selective ligand-
gated ion channels and can be activated by different stimuli. The most studied is the 
TRPV1 subtype, also known as the capsaicin receptor. TRPV1 is expressed by most 
small sensory nerves and is sensitive to heat, hydrogen ions and capsaicin (and other 
endogenous capsaicin-like substances) 
44
. Whilst immediate sensitisation is mediated 
by an increased probability of channel opening in response to these stimuli, increased 
levels of TRPV1 protein have also been observed in the mucosa of patients with some 
visceral hypersensitivity states, with or without evident inflammation
45
 
46
, including 
the oesophagi of patients with gastro-oesophageal reflux disease (GORD)
3
. Apart 
from acid, TRPV1 is also responsible for the sensation of heat from capsaicin. Most 
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patients with GORD also report sensitivity to hot drinks and spicy foods.  
 Purine receptors – P2X Purinoceptors are ATP-dependent, ligand-gated 
membrane cation channels. There are currently seven subtypes known. In particular, 
P2X3 expression in the dorsal root ganglion is increased in rats with chronic 
oesophageal acid infusion
47
.  
 ASICs – These ‘acid-sensing ion channels’ are amiloride-sensitive, voltage-
insensitive epithelial Na channels. Subtypes 1-3 are sensitive to acid and possibly 
mechanical stimuli. They have been shown to be upregulated in mucosal inflammation 
and stimulated by NGF and serotonin. One in particular, acid sensing ion channel 3 
(ASIC3), as the name suggests, has been known to sense acid (fluctuations in pH) but 
is better known as an important mechanoreceptor
48
 and nociceptor in end organs. It is 
known to be fairly ubiquitous in the central nervous system (CNS), and exists in 
sensory nerve endings
49
. However, the mechanism of action in its role as a sensory 
nociceptor has been linked to pH fluctuations
50
 
51 52
 and inflammation in the 
oesophagus and stomach in animal studies. This will be discussed further in Chapters 
2 & 3.  
 
1.5.3 Central sensitisation 
In normal circumstances, the presence of stimuli will activate the peripheral receptors 
as mentioned above. Action potentials would then be generated via activation of Na/K 
channels, and impulses will be sent to the spinal cord via peripheral afferent nerves. 
Repetitive stimulation or high intensity stimuli can cause a constant firing of action 
potential to the spinal cord
53
. Enhanced nociceptor input in turn activates intracellular 
signalling cascades within spinal dorsal horn neurones, leading to central sensitisation 
and amplified responses to noxious and innocuous inputs due to facilitated excitatory 
synaptic responses and depressed inhibition
54
 
55
 
56
. This facilitation is triggered by the 
pre-synaptic release of neurotransmitters and neuromodulators such as glutamate
57 58
, 
substance P
59 60
, brain-derived neurotrophic factors (BDNF)
61
 and prostaglandins
62 63
. 
These neurotransmitters and neuromodulators activate ligand-gated ion channels 
(NMDA-receptor-glutamate)
60
, metabotrophic receptors (metabotrophic glutamate 
receptor (mGluR)-glutamate and NK1-substance P
64
) and tyrosine kinase receptors 
(Tyrosine Kinase (Trk) B--BDNF
61
) and increase intracellular calcium via release 
from intracellular stores and calcium inflow
54
 (Figure 1.2). Consequently, calcium-
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dependent enzymes such as protein kinase A
65
, protein kinase C 
66
 and tyrosine 
kinases are activated, leading to phosphorylation of the NMDA receptors
54
. This 
dramatically changes NMDA receptor kinetics and reduces its voltage-dependent 
magnesium block
66
, thus augmenting its subsequent responsiveness to glutamate and 
increasing synaptic strength, enabling previously sub-threshold inputs to activate the 
cell
54
 
56 67
. This increase in gain alters receptive field properties and pain sensitivity, 
causing tissue hypersensitivity far beyond the site of injury.  
 
In addition to producing central sensitisation, which occurs within seconds of 
appropriate spinal dorsal horn neurone activation, nociceptive input also generates an 
activity-dependent change in transcription in the dorsal root ganglion and dorsal horn 
neurones
54 56 67
. These changes occur in response to a complex mechanism involving 
both an increase and a modification of constitutively expressed genes, as well as the 
induction of novel genes 
68
 
69
 . This phenotypic shift results in allodynia (previously, 
non-nociceptive stimuli induced pain) as well as hyperalgesia (heightened sensitivity 
to a previously painful stimulus). These changes take hours to manifest but, when 
established, lead to long-lasting changes in stimulus response characteristics. Evidence 
that central sensitisation is a major component of somatic hypersensitivity has already 
been demonstrated in human somatic pain models
70
. In animal studies, direct 
electrophysiological recordings from spinal neurones also suggest that central 
sensitisation is important in visceral hypersensitivity 
71
 
72 73
. However, until recently, 
similar studies in man were not possible due to a lack of suitable human experimental 
models and non-invasive techniques available to assess visceral afferent pathways.  
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Figure 1.2: Shows receptor mechanisms underlying the induction of central 
sensitisation. The central terminals of primary nociceptors release glutamate, 
substance P, brain-derived neurotrophic factors (BDNF) and prostaglandin E2 
(PGE2). Glutamate binds to ionotropic AMPA (Amino-Methylene-Phosphonic Acid), 
NMDA (N-Methyl-D-Aspartate) receptors and to metabotropic glutamate receptors 
(MGR). Substance P and BDNF bind to the G protein coupled neurokinin 1 (NK-1) 
receptor and the tyrosine kinase receptor B (TrkB), respectively, and PGE2 binds to 
the EP1 receptor on the postsynaptic membrane. An increase in intracellular Ca
2+
 
concentration triggers the activation of protein kinases A and C (PKA & C) and Ca
2+
-
calmodulin-dependent protein kinase (CaMKII). These kinases and tyrosine kinase 
Src phosphorylate the NMDA and AMPA receptors leading to a potentiation in 
activity. Nitric oxide (NO) is also produced, which has a positive feedback effect on 
presynaptic glutamate release. Central prostaglandin production is increased via 
arachadonic acid (AA) by cyclooxygenase-2 (COX-2) induction. 
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1.5.4 Human oesophageal models of peripheral and central sensitisation 
Specific experimental models of VPH in the human oesophagus in reaction to acid 
infusion have been described. Sarkar, et al., using either saline or acid infusion in a 
double blind randomised manner on the distal oesophagus, demonstrated a drop in 
pain threshold to electrical stimuli within the exposed distal and non-exposed 
proximal oesophagus after acid but not the saline infusion in healthy volunteers 
74
 
(Figure 1.3). In addition, a decrease in patient threshold was also demonstrated on the 
anterior chest wall after oesophageal acidification. Although the primary 
hyperalgesia/allodynia at the site of infusion is believed to be due to PS, the secondary 
hyperalgesia/ allodynia in the proximal oesophagus and anterior chest wall, distant 
from the acid infusion, is believed to be due to the sensitisation of spinal dorsal horn 
neurones
74 75
 
76
. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Shows the change in pain threshold on the upper oesophagus after 
acid/saline infusion in the lower oesophagus. (Reproduced from Sarkar et al., Lancet 
2000)
74
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Sarkar, et al. demonstrated that in patients with gastro-oesophageal reflux disease, 
oesophageal pain hypersensitivity to experimental acid infusion can be reversed by 
acid suppression with proton pump inhibitors 
77
. The mechanism of this reduced 
sensitivity to acid may be related to the fact that treatment of acid reflux removes 
peripheral afferent input to the spinal cord, which may in turn reduce the degree of 
resultant central sensitisation. Patients with functional heartburn have also been 
speculated to have heightened sensation to other peripheral inputs, such as bile reflux 
78
. However, pain sensitivity to oesophageal chemical stimuli is far from understood, 
especially when one considers that even in patients with documented acid reflux in pH 
studies, the majority of events are not perceived 
79
. 
 
Reproducibility studies with the acid-induced VPH model have demonstrated 
variations in the magnitude of sensitisation between subjects
80
. Recently, state anxiety 
was implicated as a factor that may modulate the degree of sensitisation to 
oesophageal acidification within this model
81 82
. It can be speculated that 
psychological state modulates pain sensitivity and the degree of central sensitisation in 
response to injury by moderating descending spinal inhibitory and facilitatory 
influences. 
 
Drewes, et al. demonstrated that the induction of pain hypersensitivity to acid infusion 
is also associated with enhanced oesophageal contractions
83
. The same group also 
demonstrated that acid sensitisation of the oesophagus made it more sensitive to heat 
rather than cold
84
, which may be related to the peripheral up-regulation of receptors 
such as TRPV1. Other variations to the acid perfusion model were explored and 
gender differences observed. For instance, females were shown to report a wider 
anatomical area of pain referral over the anterior chest wall after acid infusion in 
comparison to males, whereas males reported increased sensitivity to chemical and 
mechanical stimuli
85
. This is important in the clinical context in explaining gender 
differences in reporting of symptoms. It has also been demonstrated that sensitisation 
can occur in different areas of the gut after acid-induced sensitisation of the distal 
oesophagus. The oesophagus, duodenum and rectum were all more sensitive to 
mechanical distension after acid sensitisation rather than saline
86
. As the innervation 
of these organs overlaps at the level of the spinal cord, it is likely therefore that this 
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cross-sensitisation is related to central sensitisation of spinal dorsal horn neurons 
caused by the acid infusion.  
 
1.5.5 Cortical mechanisms  
A major limitation of most visceral hypersensitivity studies is that they rely on 
subjective methods of reporting sensation intensity
87
. To overcome this issue, a 
commonly used neuro-physiological technique, cortical evoked potentials (CEPs), has 
been adopted for use as a more objective correlate of oesophageal sensation. CEPs 
allow the recording of cortical neuronal electrical fields generated in response to 
peripheral nerve stimulus. Signal averaging of cortical electrical activity up to 200 
oesophageal stimuli is conducted to generate an optimal signal-to-noise ratio, and a 
temporal pattern of cortical activation is obtained. As a result of the excellent temporal 
resolution of this technique (1millisecond) it is possible to study the conduction 
velocity of afferent neuronal transmission from the oesophagus to the cortex. Using 
this technique before and after oesophageal acid infusion, a consistent reduction in 
CEP latency to oesophageal electrical stimulation has been described, which 
demonstrates that the facilitation of afferent pathway conduction accompanies the CS 
(Figure 1.4) 
88
. In a recent study in NERD and functional heartburn patients
89
, there 
was a correlation between pain threshold and acid exposure, with increased 
oesophageal sensitivity being associated with a lower DeMeester score. Thus, reflux-
negative (functional heartburn) patients had lower pain thresholds compared to both 
reflux positive patients and controls. Cortical-evoked potentials were normal in reflux-
negative patients, but significantly delayed in the reflux-positive group. This suggests 
that increased oesophageal pain sensitivity in functional heartburn patients is 
associated with heightened afferent sensitivity, as normal latency evoked potential 
responses could be elicited with reduced afferent input. Similar differentiation in the 
afferent response using cortical evoked potentials has also been shown in subgroups of 
patients with non-cardiac chest pain
90
. 
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Figure 1.4: Shows increased proximal oesophageal afferent pathway sensitivity 
following distal oesophageal acidification. Distal oesophageal acid infusion is 
associated with a reduction in the latency of the evoked potential response from the 
non-acid exposed proximal oesophagus. No change in latency occurs following saline 
infusion. These results support the involvement of central sensitisation in the 
mediation of VPH. (Reproduced with permission from Sarkar S, Hobson AR, Furlong 
PL, Woolf CJ, Thompson DG, Aziz Q. Central neural mechanisms mediating human 
visceral hypersensitivity. Am J Physiol Gastrointest Liver Physiol 
2001;281(5):G1196-202)
91
. 
 
Functional Magnetic Resonance imaging has also been used to study the brain 
processing of acid-induced oesophageal hypersensitivity. Lawal, et al. studied brain 
processing to mechanical stimulation of the proximal oesophagus following the 
infusion of acid or control buffer solution into the distal oesophagus
20
. Following 
distal oesophageal acid infusion, both subliminal and conscious levels of proximal 
oesophageal distensions caused a significant increase in brain activity in both the 
cingulate and the insular cortices in comparison to the control buffer solution
20
. This 
suggests the development of acid-induced sensitisation of the oesophagus to 
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mechanical distention and indicates that this sensitisation is accompanied by increased 
activity in brain areas processing both sensory (insular cortex) and cognitive 
(cingulated cortex) aspects of sensation.  
 
In a recent fMRI study in GORD patients
92
, acid-induced heartburn was associated 
with an increase in activity in the sensory/motor, parieto-occipital, cingulate and 
prefrontal regions, as well as the insula. Activation of similar areas was also observed 
in healthy subjects not experiencing heartburn to the administered acid infusion. 
However, activity in these regions occurred more rapidly and with greater intensity in 
GERD patients than in healthy controls in response to acid exposure, which suggests 
the presence of heightened afferent pathway sensitivity in the patients.  
 
1.5.6 Autonomic nervous system 
The role of the ANS in modulating oesophageal sensitivity has also been 
demonstrated. For instance, increased basal sympathetic activity and lower vagal 
activity, as measured by the power spectral analysis of heart rate variability, are 
associated with increased sensitivity to oesophageal acid perfusion in patients with 
NCCP compared with healthy controls
93
. In addition, the heightened sensitivity to 
oesophageal acid infusion in GORD patients, as compared to healthy controls, has 
been shown to be associated with reduced vagal tone during infusion
94
. These data 
support the concept of neuro-humoral influences on the susceptibility to symptoms 
such as heartburn. 
 
1.5.7 Stress and hormones 
Animal studies have shown that stress (early maternal separation) induces visceral 
hyperalgesia, colonic dysmotility and anxiety-like behaviour
95 96
. Stress could affect 
VPH by modulating ANS as described above. In addition, stress is also associated 
with activation of the hypothalamic pituitary axis, while the Corticotrophin-releasing 
factor (CRF) is believed to play an important role
96
 in altering the physiology, 
permeability and secretory functions of the gut
97
 during stress. Induction of stress is 
associated with increased paracellular permeability and dilated intracellular spaces 
(DIS) in the oesophagus
98
. A previous link between DIS with NERD
99
 and the 
development of symptoms of acid reflux
100 101
 has also been demonstrated. 
  PhD Thesis 2010 
 
___________________________________________________________________________________ 
 
48 
 
Furthermore, stressful situations often alter cognitive interpretation of stimuli and alter 
pain reporting
102
. 
 
 
1.6 RESEARCH RELEVANCE 
The perception of symptoms in GORD is a multi-factorial process. The origin of 
symptoms in GORD is obviously acid in the oesophagus. Acid is corrosive and the 
normal human oesophagus can sense acid but is also very resilient to it. While in most 
individuals intermittent acid exposures can cause the occasional heartburn that we all 
experience from time to time, in some individuals VPH can be triggered due to 
peripheral and central sensitisation of primary afferent and spinal dorsal horn neurons, 
causing more persistent and chronic symptoms. The future treatment of GORD 
patients’ symptoms requires comprehensive understanding and profiling of all the 
factors influencing VPH including ANS dysfunction, emotions, stress and cognition, 
all of which are current areas of research interest. 
 
1.6.1 Gaps in Knowledge 
Within the VPH model, many individual pathways and interactions still need to be 
explored further, as outlined below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research agenda in VPH 
1. Molecular markers of afferent receptor sensitisation in oesophageal mucosal 
biopsies need to be identified.  
2. The use of neurophysiological techniques to identify subgroups of patients 
with true afferent nerve hypersensitivity or psychological causes needs to be 
explored.  
3. The role of stress and autonomic nervous system in mediating oesophageal 
peripheral and central sensitisation needs elucidation. 
4. Treatment with anti neuropathic pain drugs needs to be explored in patients 
with oesophageal pain hypersensitivity refractory to acid suppression.  
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Specifically, my studies aim to explore and fill in gaps on issues in VPH that are 
clinically relevant. For peripheral mechanisms, there are still many uncertainties 
surrounding biomarkers and nerves associated with acid induced symptoms in humans 
(Chapters 1 & 2). For central mechanisms, human models have been used to induce 
VPH, but the reproducibility and problems with this model have not been 
systematically studied (Chapter 4), while a practical oral agent and how it could 
prevent VPH has never been found (Chapters 5).  
 
1.6.2  Cohort development 
The identification of both PS and CS biomarkers is important to help identify and 
classify patients where these mechanisms are predominant. This is important in 
furthering our understanding of the development of symptoms in patients with acid 
reflux, which is different from inflammation or acid exposure per se. 
 
1.6.3 Therapeutic potential 
With the identification of these biomarkers or pathways, it might be possible in some 
cases to alter the role of these factors in the development of symptoms. They can also 
be exploited as investigative tools. As mentioned, many of the changes within VPH 
have evolutionary or protective roles; therefore, potential modulation needs to be done 
with care. This is only possible if we further our understanding in PS and CS in the 
context of VPH. 
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DISTRIBUTION OF PERIPHERAL MARKERS 
AND NERVE FIBRES IN FULL THICKNESS 
SAMPLES OF HUMAN OESOPHAGUS 
 
 
2.1 INTRODUCTION 
To further explore the role of specific neuronal afferent receptors in acid-mediated 
oesophageal visceral pain hypersensitivity (VPH), in-vitro studies of full-thickness 
human oesophageal samples permit the distribution of these receptors in different 
layers of the oesophagus to be determined. These experiments form the basis of the 
selection of suitable mucosal biomarkers for subsequent studies (Chapter 3).  
 
2.1. 1 Aims and objectives 
1. To determine the distribution of neuronal elements (ganglia and nerve fibres) 
in surgically excised full-thickness oesophageal samples; 
2. To determine the distribution of protein expression for selected neuronal 
receptors (TRPV1, TRPV4, ASIC3) in surgically excised full-thickness 
oesophageal samples. 
 
2.1. 2 Rationale 
Little is known of oesophageal afferent innervations in comparison with other gut 
regions, even in rodent species, with particular difficulties obtaining full-thickness 
oesophageal tissue, which hinders studies in this area and the distribution of 
neuroreceptors in humans. In contrast, mucosal biopsies are readily available in 
humans at upper GI endoscopy. Such biopsies have value in the diagnosis of epithelial 
diseases such as cancer, dysplasia and metaplasia (Barrett’s oesophagus)103 104 and can 
also provide information on the presence of inflammatory cells in the context of 
GORD
105
. In other areas of the GI tract, notably the small and large intestine, mucosal 
biopsies have been used to provide information on the neurochemistry of terminal 
processes in relation to submucosal/myenteric intrinsic and extrinsic afferents 
106 107
 
46 
108
. Studies of visceral pain have frequently sought increases in the expression of key 
2 
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neuronal proteins involved in damage-sensing, on the basis that these are upregulated 
to induce a phenotypic switch during sensitisation
109
. Central to this premise are 
observations from basic studies of the somatic nervous system of rodents, where 
regulation of cation channels by nerve growth factor (NGF) is conferred by axonal 
transport to the periphery from the DRG 
110
 
111
 
112
 
113
 
114
. Such mature proteins might 
thus be found in increased quantities in biopsies that contain nerve endings from 
visceral primary (spinal) afferents. Although less studied than elsewhere, other 
scholars have demonstrated that small fibres in lamina propria papillae (including 
those obtained by endoscopic biopsy) can be immunostained for TRPV1 in the 
oesophagus 
3
. These studies did not, however, use full-thickness tissue to study the 
broader distribution of such proteins, which we deem necessary to determine 
accurately the size, depth and number of biopsies as well as the exact methods of 
protein quantification that would subsequently be required for future biopsy studies as 
part of the overall thesis. 
 
 
2.2  SUBJECTS AND METHODS 
 
2.2.1 National research ethics approval process 
Approval for the experiments in Chapters 2 and 3 was granted by the East London and 
the City Research Ethics Committee III (submitted 19
th
 July 2007). Dr Chua and Mr 
CH Knowles attended the interview on 19
th
 July 2007. Provisional approval was given 
subject to minor amendments. Final approval was awarded 27
th
 November 2007: 
REC: 07/H0705/67. Barts and the London NHS Trust Joint Research Office acted as 
sponsors. Data were constantly updated on the National Institute for Health Research 
(NIHR) via the UKCRN (UK Clinical Research Network) website. Further details on 
the ethical approval process are attached in Appendix 2.01. 
 
Research samples were coded and anonymised at source. A link to clinical details was 
kept by the investigator in a secure folder and as a hard copy only. 
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2.2.2 Subjects 
Ten subjects undergoing oesophagectomy for oesophageal adenocarcinoma (n = 9) 
and benign stricture (n = 1) were recruited, all of whom gave written consent for their 
involvement in the study (Table 2.1). All were male, aged 48-80 (mean 65) years. 
Eight out of the nine cancer patients had received neo-adjuvant chemotherapy. For 
oesophageal adenocarcinoma, the main combination chemotherapy was Cisplastin and 
5-Flurouracil, along with gastro-oesophageal adenocarcinoma with ECF (Epirubicin, 
Cisplastin, and 5-Flurouracil). Chemotherapy could have had a significant effect on 
epithelium and enteric neurones but it was necessary to use these samples; as it was 
only in this situation I could realistically obtain full-thickness human oesophageal 
samples (limitations of these samples discussed in section 2.4.2). Surgery was 
performed 4-6 weeks after the end of chemotherapy. The tumour stages and 
histological grades are listed in the table below. No subject withdrew consent during 
the study. 
 
Sex Age Chemo-
therapy 
Reflux Barrett’s Diagnosis Stage Histology 
Grade 
M 48 No No No Benign stricture N/A N/A 
M 74 Yes No Yes Adenocarcinoma T3N1 Poorly 
differentiated 
M 71 Yes Yes Yes Adenocarcinoma T1N1 Well 
differentiated 
M 69 Yes No No Adenocarcinoma T2N3 Poorly 
differentiated 
M 59 Yes No No Adenocarcinoma T2N0 Poorly 
differentiated 
M 57 Yes No No Adenocarcinoma T1N0 Well 
differentiated 
M 69 Yes Yes No Adenocarcinoma T3N1 Poorly 
differentiated 
M 65 Yes No No Adenocarcinoma T2N0 Poorly 
differentiated 
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M 61 Yes No No Adenocarcinoma T3N0 Poorly 
differentiated 
M 80 No No Yes Adenocarcinoma T2N0 Poorly 
differentiated 
 
Table 2.1: Clinical and tumour details of the 10 oesophagectomy samples 
 
2.2.3 Tissue acquisition and fixation 
Surgical samples were collected immediately after resection from theatre and 
transferred directly to the Department of Morbid Anatomy, Barts and the London 
Trust. Whole specimens were examined by a Consultant Pathologist with sub-
specialist expertise in GI pathology (Dr Joanne Chin-Aleong). Following gross 
inspection, an area at the margin of the specimen was identified for research and 
summarily sharp dissected from the main specimen (avoiding histological diagnostic 
compromise). The samples were invariably distal oesophago-gastric samples from 
laparoscopic assisted oesophagectomy. The full-thickness oesophageal samples were 
taken from the proximal margin of the resected samples and were therefore mainly 
distal oesophageal samples. The distal margin would constitute gastric border. Two 
blocks were created from each specimen by division with one half snap-frozen in 
liquid nitrogen and stored at -80 C and another paraffin fixed (methodology below).  
 
2.2.4 Tissue preparation 
Formalin fixation was performed in 10% neutral formalin for at least 24 hours, with 
the specimen orientated and pinned mucosa-up on a small piece of cork to avoid 
contraction. Fixed samples were then embedded in paraffin cassettes by the laboratory 
technicians and stored for future sectioning. (For the protocol regarding paraffin 
fixation, please refer to Appendix 2.03). Three to five micron sections were cut using 
a standard microtome on request. Slides were cut by laboratory technicians and 
incubated in 37 ºC before immunohistochemistry staining.  
 
2.2.5 Control tissues 
Formalin-fixed, paraffin wax-embedded human colon, kidney and liver samples, as 
well as rat cerebella and dorsal root ganglia (DRG), were obtained from the Pathology 
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group, Blizard Institute of Cell and Molecular Science (BICMS), Queen Mary 
University, London control tissue bank. 
 
2.2.6 Immunohistochemistry methods 
 
2.2.6.1 Background to method 
Immunohistochemistry (IHC) is a scientific method for detecting antigenic proteins in 
cells and tissues, using labelled antibodies as reagents for the optical detection and 
localisation 
115
. As such, it is an indirect method of antigen detection and the 
specificity of antibody binding to the chosen epitope is paramount. 
Immunohistochemistry involves a number of steps. Samples collected are often ‘fixed’ 
(e.g. paraffin fixation) or frozen. ‘Unmasking’ of antigens which may be hidden by 
fixation process (e.g. formalin cross-links) with antigen retrieval is the necessary first 
step. A number of techniques usually involving heating and alkaline treatment have 
been described. Although the actual molecular mechanisms underlying the processes 
for antigen retrieval are not known, antigen retrieval methods are thought to reverse 
protein modification inflicted by formalin during the fixation process 
116
.  
 
Following antigen retrieval, all samples are blocked with normal horse serum to 
provide a non-specific peptide block. In some cases, specific serum compatible to the 
choice of secondary antibody should be used. An additional avidin/biotin block is used 
if the positive control happens to be derived from the kidney or liver, each of which 
contains endogenous biotin
117
. After the blocking steps, the specific primary antibody 
is applied and incubated with the tissue. Excess antibody matter is washed prior to the 
application of a species-specific secondary antibody, which is conjugated to a tag such 
as biotin or a fluorophore. This secondary antibody complex is applied and binds to 
the primary antibody before the application of a detection reagent containing a 
chromagen such as diaminobenzidine (DAB) or fluorophore that binds to the antibody 
conjugate. Gill’s haematoxylin provides a contrasting counter-stain of nuclei and 
cellular structures to give strong colours that aid microscopic visualisation. Primary 
antibody specificity should be checked using positive control tissue that is known to 
contain the antigen. Negative controls, where the primary antibody is omitted, should 
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also be included in each experiment
118
. The compositions of all solutions and reagents 
are detailed in Appendix 2.02, and kits are now available to simplify methods. 
 
  
2.2.6.2 Indirect immunohistochemistry kit-based system 
Indirect immunohistochemical staining was performed using a kit-based system. 
Initially, this was known as the ABC kit (Vectastain Universal Elite ABC kit, Vector 
Laboratories, Burlingame, California, USA); however, the same company updated the 
kit to a newer version, known as the ‘RTU kit’ (R.T.U. Vectastain Universal Elite: 
Vector Laboratories, Burlingame, CA, USA), which is also an avidin-biotin-
peroxidase complex method. 
 
In brief, tissue sections were de-waxed in two changes of xylene for 2 minutes and 
dehydrated in two changes of industrial methylated spirit (IMS) for another 2 minutes. 
After washing in running tap water for 5 minutes, thermal antigen retrieval was 
carried out by microwaving or water bathing sections in a citrate buffer (Vector 
Laboratories, Burlingame, California, USA) for a duration specified in specific 
optimisation schedules. Sections were allowed to cool for 5 minutes and washed again 
in running tap water for 5 minutes. Endogenous peroxidase activity was blocked by 
placing sections in methanol containing 3% H2O2 for 15 minutes. After further 
washing in running tap water for 5 minutes and soaking in the wash buffer (Dako, 
Cambridgeshire, UK) for 2 minutes, the sections were then incubated in normal horse 
serum (supplied in the kit) for 20 minutes at room temperature. Excess blocking serum 
was tipped off and the sections were incubated with primary antibodies in a dilution 
specified in the optimisation schedule, usually for 40 minutes at room temperature, 
unless otherwise stated. Sections incubated with antibody diluent served only as 
negative controls. Primary antibodies were washed off with wash buffer and the 
sections incubated with secondary biotinylated antibodies from the kit (Universal 
secondary antibody-anti rabbit and mouse, Vector Laboratories, Burlingame, 
California, USA) for 30 minutes at room temperature. The secondary antibody was 
washed off with wash buffer and sections incubated in avidin complex solution (in the 
kit) for 30 minutes at room temperature, washed again with wash buffer and then 
incubated in diaminobenzidine (DAB) solution (Bio-Genex-Laboratories, San Ramon, 
California, USA) for a further 5 minutes. After further washing in running tap water 
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for 5 minutes, the sections were counter-stained in Gill’s haematoxylin for 2 minutes, 
washed in running tap water for 5 minutes, dehydrated twice in alcohol for 2 minutes, 
cleared twice in xylene for 2 minutes and mounted in Canada balsam (VWR 
International, Leicestershire, UK).  
 
2.2.7 Visualisation of immunostaining (microscopy) 
All 10 samples were examined microscopically on all antibodies. Sections were 
analysed at magnifications of X10, X25 and X40 using a light microscope (Leitz 
Dialux 20, Leica Microsystems UK Ltd., Milton Keynes, UK). The presence and 
distribution of immunostaining in epithelial cells, nerve fibres and ganglia were noted, 
and a representative area for each gut region was photographed with a digital camera 
using the Leica IM50 Image Manager software (Leica Microsystems, UK). All 
specimens were reviewed by me and independently by another doctoral student (Dr 
Andrew Hubball). They were randomly selected to be examined by a post-doctoral 
research fellow (Dr Madusha Peiris) to check the findings. 
 
2.2.8 Antibodies  
 
2.2.8.1 Generic neuronal markers 
In order to map the distribution of neuronal endings and cell bodies in the full 
thickness oesophageal tissue, the generic nerve marker protein gene product 9.5 (PGP 
9.5) was used. PGP 9.5 is a member of the ubiquitin hydrolase family of proteins 
known to be confined to neural and neuroendocrine cells
119
. PGP 9.5 can be used to 
gain a measure of the total neural count for subsequent determination of functional 
subsets of neurons using other expressed proteins
120
. 
Synaptophysin is a glycoprotein present in the membrane of neuronal pre-synaptic 
vesicles in the brain, spinal cord and retina,  adrenal medulla vesicles, neuromuscular 
junctions and endocrine cells
121
 
122 123
. It is thus employed in IHC to label synapses
124
 
125
. The optimisation schedule for these two antibodies had already been largely 
determined by laboratory staff. Details of the antibodies and concentrations are shown 
in Table 2.2.  
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Antibody  Kit & 
Dilution 
Positive 
control 
Clonality  Antigen retrieval 
PGP 9.5, 
Serotec, 
Kidlington UK 
RTU kit 
1:2000 
Rat 
cerebellum 
Polyclonal rabbit 
anti-human  
 
- microwave 10 
minutes 
Synaptophysin, 
Abcam, 
Massachusetts, 
USA 
ABC kit  
1:200 
Rat 
cerebellum  
Polyclonal rabbit 
anti-rat  
- microwave 25 
minutes 
 
Table 2.2: Generic neuronal antibodies and optimisation schedule 
 
2.2.8.2 Specific neuronal receptors 
Within the full thickness human oesophagus, the ubiquity, specificity and relationship 
between these markers and nerves needed to be explored. Apart from the relevance of 
determining the overall distribution, the feasibility and reproducibility of these 
receptors in small and superficial biopsy samples needed to be validated for 
subsequent studies. Immunostaining was performed for TRPV1, TRPV4 and ASIC3. 
A schedule of all antibodies is shown in Table 2.3. 
 
TRPV1 
Significant problems were encountered for TRPV1 in respect of unreliability and poor 
specificity of antibodies with high variability between manufacturers and production 
batches. In total, four different commercially available antibodies were tested. Despite 
assistance from more experienced scientists, it was impossible to stain reliably using 
TRPV1 (see discussion), with the exception of a single batch of antibody from 
ThermoRicher Leicestershire, UK, which specifically stained the positive controls – 
human DRG (selective staining of small neurons) and colonic neurons (as previously 
published
46
) – and produced a band at 95KPa (as predicted)126 127 using Western 
blotting (Appendix 2.07). A subsequent antibody from the same commercial supplier 
failed to yield specific staining in the oesophagus, and on subsequent retesting as 
above failed also on controls and blotting. Immunostaining using the GSK, Abcam 
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and Neuromics TRPV1 antibody is included preliminarily, but the results are critically 
discussed below. A schedule of antibodies is shown in Table 2.3. 
 
Antibody  Kit & Dilution Positive 
control 
Clonality and 
Immunogen 
Antigen 
retrieval 
TRPV1 
GSK 
ABC kit (IF) 
1:1000, 24 hr 
Human 
colon/ 
Rat DRG 
Rabbit anti-human 
TRPV1 
- microwave 
25 minutes 
TRPV1 
Abcam 
Massachusetts 
USA 
ABC kit (IF) 
1:3000 
 
Human 
colon/ 
Rat DRG 
Polyclonal rabbit 
anti human (amino 
acid 602 076 
TRPV1) 
-microwave 
25 minutes 
 
TRPV1 
Neuromics, 
Minneapolis, 
USA 
ABC kit (with 
species specific 
secondary 
antibody) 
1:8000, 24 hr 
 
Human 
colon/ 
Rat DRG 
Polyclonal rabbit 
anti-rat (amino 
terminus of 
TRPV1)  
- microwave 
25 minutes 
TRPV1 
ThermoFisher 
Leicestershire, 
UK 
RTU kit 
1:500 
 
Human 
colon/ 
Rat DRG 
Polyclonal rabbit 
anti-human 
(TRPV1) 
- microwave 
10 minutes 
Only one batch of ThermoFisher antibody produced a band at the predicted range in 
Western blotting with good neuronal staining on positive control (DRG and colon). 
The Western blotting band is attached in Appendix 2.07 for reference. 
 
Table 2.3: TRPV1 antibody optimisation schedule for four separate antibodies 
 
TRPV4 
Recommended optimisation of TRPV4 was available in the laboratory, but my own 
run of optimisation of this antibody was conducted on a human colon prior to use in 
my research samples. 
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ASIC3  
Recommended optimisation of ASIC3 was available in the laboratory using a dilution 
of 1:25, but my own run of optimisation of this antibody, conducted prior to use in the 
samples, confirmed a dilution of 1:50. The manufacturer recommended a human 
kidney as a positive control, so using this dilution we achieved a good comparable 
standard of positive control. As this dilution was considered high, the manufacturer 
was contacted. Staining of the positive control was comparable, but with different 
laboratory protocols the final dilution used varied. 
 
Antibody  Kit & Dilution Positive 
control 
Clonality and 
Immunogen 
Antigen 
retrieval 
TRPV4 
Millipore 
(Chemicon), 
Massachusetts, 
USA 
ABC kit 1:20 
RTU kit 1:50 
Human 
liver 
Polyclonal rabbit 
anti-rat (amino 
acids 853-871 of 
TRPV4) 
ABC-
microwave 25 
minutes 
RTU- water 
bath 40 
minutes 
 
ASIC3 
Abcam, 
Massachusetts 
USA 
RTU kit 1:50 Human 
kidney 
Polyclonal rabbit 
anti-human (N-
terminal amino 
acids 73-122 of 
ASIC3)  
- microwave 
10 minutes 
 
 
Table 2.4: Specific antibodies and optimisation schedule for TRPV4 and ASIC3 
 
 
2.3  RESULTS 
 
2.3.1 Histology of the oesophageal mucosa 
H&E staining confirmed a thick squamous epithelial layer (approximately 35 cells 
thick), although there was variation between individuals and the thickness of the 
epithelium.  
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Figure 2.1: H&E staining of a representative oesophageal mucosa, demonstrating the 
epithelial layer and normal cellular morphology. Magnification X25. 
 
 
2.3.2 Generic neuronal markers 
 
2.3.2.1 PGP 9.5  
Ganglia and neurons: Within the distal oesophageal myenteric layer, ganglia were 
clearly identified and well outlined by PGP 9.5 staining. Ganglionic density was 
measured at a median 6 per 5mm
2
 (range 3-11 per 5mm
2
), more than previous reports 
in 1992 of 2.8 ganglia per 10mm
2
 in the distal oesophagus
128
, perhaps due to technical 
improvements. Our examination area was limited to 5mm
2 
due to the limited length of 
tissues vs. total sample area. Individual cell bodies were easily identified with a 
median of 4 neurons per ganglion (range 2-6 neurons per ganglion), which was more 
consistent with previous reports of 5 neurons per ganglion
128
.  
 
Nerve fibres: PGP 9.5 stained numerous small nerves in the sub-epithelium. These 
extended into the epithelial papillae, but were absent from the epithelium. This pattern 
was observed in all 10 samples. 
    
 35 cells thick 
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Figure 2.2: PGP 9.5 in a human oesophagus. (A) Nerve endings in lamina propria 
X10,(B) Neurons in lamina propria X25 (note the absence of nerve fibres in the 
epithelial layer). (C&D) Myenteric ganglia staining, both images X 25 magnification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
C D 
A 
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2.3.2.2 Synaptophysin 
Synaptophysin stained abundant synapses around the neurons within the myenteric 
ganglia. Elsewhere they were not detected. Notably, as with PGP9.5, no staining was 
evident within the epithelium. These findings were again consistent for all 10 samples. 
 
 
Figure 2.3: (A) Synaptophysin in human oesophagus, myenteric ganglia, 
magnification X 25. (B) Epithelium X10, with no synapses detected in the epithelial 
layer. 
 
 
2.3.2 Specific neuronal receptors 
 
2.3.2.1 TRPV1  
Immunohistochemistry results for GSK, Abcam and Neuromics antibodies accepting 
unreliability are shown in Figure 2.4. In these results, neuronal TRPV1 was detected 
occasionally on the luminal surface of epithelium. Epithelial TRPV1, although more 
regular, exhibited a peculiar pattern in the superficial epithelium, which was not 
considered to represent specific immunoreactivity. Using the Neuromics antibody, we 
noted weak staining of neuronal cell bodies within the myenteric ganglia and also of 
the basal layers of the squamous epithelium, although this varied in intensity (Figure 
2.5). 
 
 
 
 
A B 
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Figure 2.4: Human oesophageal TRPV1 staining with immunofluorescence with; (A) 
GSK antibody (B) Abcam antibody staining mainly epithelial cell cytoplasm. No 
ganglionic or neuronal staining detected. X 40 Magnification (Immuno-fluorescence 
with frozen sections courtesy of Dr Madusha Peiris) 
 
 
 
 
 
 
Figure 2.5: (A) Neuromics TRPV1 in human oesophagus; lack of staining in 
epithelium and sub-epithelium with no staining of TRPV1 immunoreactive nerve fibres 
detected, X 25 magnification. (B) TRPV1 staining ganglion in myenteric plexus X 25 
magnification. 
B A 
A B 
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2.3.2.2 TRPV4 (Figure 2.6) 
TRPV4 antibody stained the cytoplasm of myenteric neurons in all 10 samples. Weak 
nuclear staining was also detected in most cells throughout the squamous epithelium. 
In addition, in a sample with Barrett’s metaplasia, TRPV4 staining was much stronger 
in the epithelium.  
 
Figure 2.6: (A) TRPV4 in human oesophagus, epithelium and lamina propria, X25 
magnification. (B) TRPV4 in human oesophagus, ganglia in myenteric plexus, X25 
magnification.  
 
2.3.2.3 ASIC 3 (Figures 2.7-2.8) 
Strong cytoplasmic staining was detected in myenteric ganglia neurons in all 10 
samples (Figure 2.8). Myenteric ganglia were positive for ASIC3 (Figure 2.8). No 
clearly distinct staining of nerve fibres was observed in the sub-epithelium in 
comparison with PGP9.5 (Figure 2.7). ASIC3, however, produced strong epithelial 
staining with noticeable variation in different samples (from intense to almost 
negligible). In addition, apart from the difference in intensity of staining, there were 
also differences in the distribution and morphology of ASIC3 staining in the 
epithelium, which will be discussed in Chapter 3. This difference may represent 
different states of receptor activation and could be exploited in the biopsy study with 
patients. 
 
 
 
 
B A 
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Figure 2.7: Paired images from consecutive cuts of human oesophagus stained with 
ASIC3 (A1, A2, A3) and PGP 9.5 (B1, B2, B3) in X10 magnification. Lack of overlap 
between areas stained with ASIC3 and PGP 9.5 suggested minimal ASIC3 
immunoreactive neuronal endings. The 3 pairs represented the spectrum of ASIC3 
staining intensity in the epithelium; A1- high intensity ASIC3 staining, A2-medium 
ASIC3 staining and A3- minimal ASIC3 staining.  
    
A1 B1 
A2 B2 
B3 A3 
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Figure 2.8: ASIC3 staining in deep myenteric layers of full-thickness oesophageal 
samples showing neuronal ganglia. Magnification X25. 
 
2.4 DISCUSSION 
 
2.4.1 Summary of immunohistochemical staining 
The main findings of immunostaining are summarised in Table 2.5.  
Antibody Ganglia Neurons Epithelium 
PGP 9.5 + + - 
Synaptophysin +(periganglionic 
synapses) 
- - 
TRPV1 +/- - +/- 
TRPV4 + - +/- 
ASIC3 + - + 
 
Table 2.5: Summary of antibody staining using IHC in human full-thickness 
oesophageal samples 
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2.4.2 Limitations 
The study has several significant limitations that must be acknowledged and 
discussed.  
 
Human samples: these were necessarily obtained for patients with disease. Nine 
patients had adenocarcinoma and one had a benign stricture. For each patient, it could 
be supposed that chronic acid exposure may have contributed to the disease process, 
although only two were documented to have symptomatic GORD. Indeed, three 
showed evidence of Barrett’s metaplasia, which is a consequence of chronic GORD. 
Furthermore, eight had undergone neo-adjuvant chemotherapy with ECF combination 
chemotherapy. Chemotherapeutic agents suppress mitosis including in the epithelium, 
although in all patients usually 4-6 weeks lapsed between the completion of 
chemotherapy and operation. Adenocarcinoma of the oesophagus can also affect 
receptor expression in the human oesophagus and receptors have been used as 
predictors of treatment responses to neo-adjuvant chemotherapy in oesophageal cancer 
129
. Chemotherapy is also well documented to induce neuronal damage including 
peripheral neuropathy 
130
 
131
, which could affect quality of my neuronal staining. 
Chemotherapy was also shown to be associated with vagal changes
132
 and in the 
human oesophagus, shown to induce dysphagia, further suggesting neuronal 
involvement
133
. In summary, these specimens from patients receiving neo-adjuvant 
chemotherapy cannot be considered ‘normal’.  
 
The IHC biopsies were obtained from slightly different areas of the oesophagus, 
depending on the availability of a specimen that could be safely dissected away from 
the main structure without compromising routine diagnosis and oncological staging. 
Nevertheless, all biopsies came from the distal oesophagus, as evidenced by the 
diagnoses of adenocarcinoma and the types of surgery performed, namely 
laparoscopic assisted oesophagectomy (as mentioned in section 2.2.3). This is 
important because neuronal distribution may differ from proximal to distal 
oesophagus. From the lower oesophagus towards the lower oesophageal sphincter 
(LOS), there is evidence that atypical myenteric plexus localisation causes spuriously 
low neuronal counts in lower oesophagus in opossum study
134
. This is believed to 
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result from myenteric plexus lying in more variable planes at it approaches the 
LOS
135
. 
 
The method used, IHC, is an indirect measure of the presence and distribution of 
protein in the sample. IHC has limitations concomitant on the quality of the 
antibodies, which is especially relevant to the study of human samples where 
polyclonal antibodies are most commonly employed (as in this study). In this protocol, 
there were several limitations including:  
a. The antibodies were not validated using other methods. While PGP9.5 and 
synaptophysin were already well-validated in the laboratory (and produced 
specific staining in the expected distribution), the antibodies to neuronal 
receptors were not. A known positive control and negative control were 
used for all antibodies; however, other methods such as the purchase of a 
blocking peptide were not. Thus, although the basic method can be deemed 
successful, it is not possible to conclude that binding is specific to the 
receptor studied. 
b. Immunohistochemical protein expression was not confirmed by other 
methods such as Western blotting
136 137
 or by relating findings to the 
expression of mRNA using RT-qPCR
136 137
 
126
 or other techniques. This 
would not be of relevance to neuronal expression (without considerable 
enrichment, e.g. by laser capture micro-dissection), but could have been 
used to study epithelial expression – this is further discussed in Chapter 3. 
c. Variable techniques of fresh frozen section versus paraffin fixed samples. 
This applied mainly to TRPV1 staining as discussed in 2.4.3.2.  
 
The proteins studied were not comprehensive in respect of those that could be of 
relevance to acid sensing in the human oesophagus. The classes of relevant receptors 
were discussed in Chapter 1. Those selected were chosen on the basis of more 
extensive evidence from previous studies, as outlined below. 
 
2.4.3 Previous studies and current evidence 
Despite the limitations outlined above, the findings merit discussion in the context of 
previous studies, with particular focus on the anatomical location of these receptors. 
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2.4.3.1 Oesophageal neuronal distribution based on immunohistochemical markers 
The main finding was that our prior assumption that nerves would be evident within 
the epithelial layer was clearly incorrect. This assumption was based mainly on 
TRPV1 studies
126 138
. On the basis of H&E staining, standard histological texts are not 
helpful in describing the localisation of small sensory nerve endings in the 
oesophageal epithelium. Classic histopathological descriptions and visualisations of 
oesophageal innervation have been limited to the intrinsic plexi including submucosa 
plexus (Meissner’s) and myenteric plexus (Auerbach’s), as described in Chapter 1. 
The distinction between these plexuses in isolated small clinical samples is recognised 
as being difficult – even by histopathologists – due to the often thick muscularis 
mucosae in the human oesophagus 
4
.  
 
As standard H&E is not the best method for detecting small nerve endings, more 
specialised methods have been used including silver staining and, more recently, 
specific antibodies such as PGP 9.5 or peripherin as part of the immunohistochemistry 
process. Using silver staining of nerves, a detailed study looking at the human 
oesophagus, visualised nerves in the sub-epithelial lamina propria
139
. More 
conclusively, using the same techniques as in the present study (PGP 9.5 
immunohistochemistry) for human volunteers and patients, Newton et al. found that 
nerve endings did not penetrate the epithelium, but innervation in the sub-epithelium 
(especially the papillae) did increase in the presence of inflammation
140
. The former 
observation is consistent with the PGP 9.5 results of the current study. 
 
2.4.3.2 TRPV1 
Based on a pilot study demonstrating the up-regulation of TRPV1 immunoreactive 
nerve fibres in patients with erosive oesophagitis compared to normal volunteers
3
, we 
originally aimed to characterise the distribution of TRPV1 immunoreactive nerve 
fibres in human oesophageal biopsy samples, and then correlate the derived data with 
detailed symptoms as well as endoscopic disease classification. As a pilot to a study of 
biopsy samples, it was necessary to chart distribution in full-thickness tissues (for 
validation purposes). Since this time, two key publications on the subject have 
emerged. In 2006, Bhat & Bielefeldt demonstrated that increased immunoreactive 
TRPV1-free nerve endings in epithelium and papillary areas were associated with 
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increased acid exposure time in patients with GORD, but not correlated with symptom 
severity assessed by questionnaire
141
. 
 
In a more recently published study, oesophageal mucosal biopsies from patients with 
NERD and EO demonstrated increases in TRPV1 in both RT-qPCR and Western 
blotting 
126
 compared to healthy volunteers. Immunohistochemistry was completed to 
control for inflammatory cells, but not for the localisation of TRPV1 expression. 
Furthermore, no figure was given showing either TRPV1 immunoblotting or 
immunostaining. The antibody (Millipore, Massachusetts, USA) was tried within our 
department but failed to produce satisfactory immunoblotting or staining. Thus, 
although this increase correlated with acid exposure time, as well as symptom severity 
in patients with GORD
126
, the quantification methods (without describing distribution) 
of TRPV1 may be due to epithelial TRPV1 as opposed to its neuronal counterpart. 
Assuming that the expression of TRPV1 shown in this study is not methodologically 
flawed, it still remains much more likely that the authors described epithelial 
expression. This very important point was discussed and accepted by Guarino, et al. as 
a likely possibility. They also accepted that neural tissues were unlikely to be present 
in biopsy tissues (consistent with our findings, i.e. without enrichment, there are few if 
any neuronal elements in mucosal biopsies).  
 
In this study, we have mainly used paraffin-fixed samples. Frozen sections were used 
with the immunofluorescence technique using GSK and Abcam antibodies. These 
antibodies using fresh frozen sections indeed yielded better quality staining of TRPV1 
compared to those using paraffin fixed sections (Neuromics and Thermo-Fisher). The 
GSK antibody produced the best quality staining but unfortunately this went out of 
production. It is noteworthy to mention this was the antibody of choice in other 
recently published studies in TRPV1 in human gastro-intestinal tract
109
 
3 45
. The highly 
variable technique between studies could explain for variable observations. All 
antibodies still produced epithelial TRPV1 staining rather than neuronal. Neuronal 
TRPV1 was noted in deep myenteric layer with only Neuromics antibody. The 
significance of epithelial TRPV1 staining is discussed in section  2.4.4.2.   
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2.4.3.3 TRPV4 
In the mouse gastrointestinal tract, using in-situ hybridisation methods, mRNA- 
enriched TRPV4 nerve fibres were localised in the serosal aspect of the colon, but not 
the mucosal nerves believed to be important in mechano-sensation in the colon
137
. 
TRPV4 protein has also been described in rat peripheral sensory nerves, although 
requiring extensive preparation
142
. In this study, the role of TRPV4 in nociception 
induced by hypotonicity was explored. Neuronal TRPV4 was believed to be 
upregulated the same way as neuronal TRPV1 – in the DRG and transported 
peripherally to the relevant sensory nerves. In this study, TRPV4 was ligated for three 
days to dampen the distal transport of TRPV4, and only with this measure was TRPV4 
visualised in the saphenous nerve proximal to ligature
142
. In a separate study, TRPV4 
was found in mouse DRG, but only in 10% of the neurons found mainly in the lung, 
kidney and sensory organs such as the skin, tongue and cochlear
143
. Unsurprisingly, 
non-neuronal TRPV4 was detected in areas in association with fluid such as renal 
cortical cells surrounding the ventricles in brain
144
 and the bladder
145
. Our results, 
employing simple immunohistochemistry, showed that oesophageal ganglionic 
staining was occasional. 
 
2.4.3.4 ASIC3 
Immunoreactive ASIC3 has been clearly demonstrated to be present in rat DRG as 
well as 20.6% of nodose (vagal) ganglia
146. Further evidence of neuronal ASIC3’s co-
existence with Calcitonin gene-related peptide (CGRP) hints towards its role as a 
nociceptor, while its existence in metaboreceptive neurons suggests a role in acid 
sensation 
51
. ASIC3 in the rat oesophagus was detected in the epithelium (prickle cell 
layer), nerve fibres and neurons, but only in the deep myenteric layer
136
. This is fairly 
consistent with our findings in humans. 
 
 
2.4.4 Interpretation of results 
 
2.4.4.1 Oesophageal mucosal nociception 
The most striking and robust finding of this study was the absence of neuronal 
elements within the epithelial layer. This finding was unexpected based on previous 
publications
3 138
, and necessarily presented a major problem for anticipated future 
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investigations (Chapter 3), since the planned mucosal biopsies could not be used to 
study nerves. However, perhaps this finding is not so surprising. The oesophagus, with 
its deep squamous epithelium (from our samples about 35 cells thick on average), is 
presumably teleologically able to withstand swallowing potentially very hot or cold 
hazardous substances and also because of its adjacency to an organ whose pH varies 
from 1.4-2.9 
147
 and whose intervening barrier is acknowledged not to be absolute 
(even in the absence of significant GORD, humans still have some acid exposure)
148 
149
. Thus, from an evolutionary perspective, it would be deleterious for nerves to lie in 
a position where they might be responsive to such environmental changes but unable 
(unlike the buccal cavity) to readily expel the offending content.  
 
Nevertheless, it is a fact that the oesophagus is a site of acute algesia in response to 
noxious stimuli – anyone who has swallowed a hot potato or very cold drink knows 
this, and numerous studies of healthy volunteers and patients confirm responses to 
polymodal stimuli such as distension, electrical and thermal stimulations
15 150 151
 . 
Furthermore, it is a site of chronic pain from infiltration, e.g. by a tumour
152 153
 and, of 
course, more commonly by GORD 
154 155
. 
 
The question of how stimuli reach the sensitive nerve endings in the sub-epithelium to 
activate them, and perhaps lead to peripheral sensitisation, is pertinent. This 
facilitation of stimuli across the mucosal epithelium may broadly occur due to three 
separate, additive or co-operating processes: 
 
 Dilated intracellular spaces (DIS) facilitate the access of acid to nerve endings: 
This now well established mechanism is supported by three studies on rabbits by 
the Siffrim group in Leuven, which used in-vitro permeability studies and electron 
microscopy to evaluate DIS. In response to acid, DIS is potentiated by bile salts in 
short duration exposures
156
. Secondly, such exposures lead to DIS in the non-
exposed proximal oesophagus
157
. Finally, this process is greatly augmented by 
concomitant stress conditions
98
.  
 Epithelial erosions permit the direct access of acid stimuli to nerves: Erosive 
oesophagitis and inflammation are often associated with pain. Direct access of 
stimuli to the nerve endings by breaks in epithelial integrity could lead to PS and 
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therefore increased immunoreacting TRPV1. This theory, although attractive, is 
not supported by evidence. Several studies attest to greater sensitivity in NERD 
rather than EO groups of patients
158
. In addition, one study demonstrated that 
patients with NERD often report more severe  acid symptoms compared to EO 
patients 
159
. Further, a study of patients with EO showed these to be hyposensate to 
mechanical stimuli compared to normal volunteers
150
. Thus, an intact epithelium 
may be associated with more PS than one that is demonstrably eroded.  
 Epitheliogenic nociception: The concept that an intact superficial epithelium has 
intrinsic mechanisms of transducing damaging stimuli to underlying nerves is 
receiving increasing attention following studies that show that in-vitro mucosal 
preparations (e.g. cat oesophagi) can respond to acid on the luminal surface by the 
basal secretion of inflammatory mediators such as Substance P, CGRP
160
 and the 
platelet activating factor (PAF) 
161
. Such responses could be experimentally 
blocked by the TRPV1 antagonist IRTX. The same study went on to show the 
presence of TRPV1 in the epithelium by immunoblotting
161
. A similar study in 
relation to PAF release was very recently performed in a human oesophageal 
epithelial cell line
162
. This line of evidence, if true, has relevance to the findings 
below. 
 
2.4.4.2 TRPV1 
The problems of specificity with various TRPV1 antibodies were covered above. In 
short, we were unable to show any convincing immunostaining for TRPV1. On this 
basis, the immunoreactive TRPV1 nerve was dropped as a useful biomarker for 
studies in Chapter 3. The question of whether superficial epithelial TRPV1 expression 
(as noted with one antibody) has true functional relevance in nociceptive signalling is 
discussed below. 
 
There is currently no reason to believe why epithelial TRPV1 should not respond to 
the same stimuli as neural TRPV1 such as heat, acid and capsaicin. For instance, one 
animal study showed that complete knockout of TRPV1 attenuated oesophagitis in 
mice
163
. While this may be the case, epithelial TRPV1 challenges the current 
understanding of PS involving the retrograde activation of messages from the 
oesophagus to DRG, and increased protein synthesis in the spinal cord and 
downstream to the nerves. TRPV1 activation, and therefore PS, could occur within the 
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epithelium itself, which is supported by emerging evidence as described above in 
epitheliogenic transduction. Even with a reliable antibody, this could only be explored 
using mRNA techniques to explore actual up-regulation. A previous study by Guarino, 
et al. addressed this relationship between protein and mRNA. The authors accepted 
that the protein measured in immunoblotting could well be epithelial TRPV1, as it was 
not visualised by immunohistochemistry. This again added to the evidence and 
strength of argument for epithelial TRPV1. Crucially for a mechanistic study, RT-
qPCR should be ideally controlled with specific and serial timing after sensitisation. In 
patients this is not realistic, so I did not pursue this course of action in the biopsy 
study.  
 
2.4.4.3 TRPV4  
TRPV4 has been shown to be an osmoreceptor
144
 and a mechanoreceptor
164
. In the 
mammalian viscera, evidence of the involvement of TRPV4 receptors in VPH comes 
from mechanical distension of the colon in rodents
165 166
 
137
. The role of TRPV4 in 
mechano-sensation could be relevant in the specific context of VPH and functional GI 
conditions in general. 
 
Expression of TRPV4 has been shown to be low in mouse gastro-oesophageal vagal 
afferents, with knockouts not showing altered vagal function to mechano-sensation, 
137 
167
 in contrast to reduced behavioural responses to somatic pain 
143
. To the best of our 
knowledge, there are no morphological studies of TRPV4 immunostaining in human 
full-thickness oesophagi. Although our findings suggest that TRPV4 is localised to the 
myenteric ganglia and basal epithelial layers, the relevance of this observation in the 
context of acid-induced oesophageal hyperalgesia is unfortunately not substantiated by 
animal studies. 
 
2.4.4.3 ASIC3 
ASIC3, as its name suggests, is considered an important acid-sensing ion channel and 
seemed a logical target for study. The current results also show varying intensity of 
ASIC3 staining in the epithelium of a full-thickness oesophagus as well as different 
morphology in cellular expression. Currently, there is strong evidence for ASIC3 as a 
mechano-sensitive receptor in mouse vagal gastro-oesophageal afferents
48
. Of course, 
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there are potentially numerous other epithelial receptors apart from ASIC3; 
nevertheless, such findings are in keeping with ASIC3 having a role for 
mechanoreceptors in pathological acid reflux, since GORD has a continuum of 
motility disturbances associated with poor coordination and inappropriately high intra-
gastric pressure and lower oesophageal relaxation. Increased ASIC3 in patients with 
more severe acid reflux should (in theory) have scientific justification and relevance in 
the context of VPH, as it is involved in both sensation and motility. More recently, the 
role and evidence of epithelial ASIC3 in the oesophagus and acid-related VPH have 
emerged, making it an even more suitable candidate. This will be discussed further in 
Chapter 3. 
 
 
2.5 CONCLUSIONS 
On the basis of the study of a full-thickness human oesophagus, and accepting 
limitations, it can be concluded that: 
1. There are no (or at least very infrequent) nerve fibres in the oesophageal 
epithelium based on established neuronal markers; 
2. Of the neuronal receptors stained, only ASIC3 had the potential for study in 
mucosal biopsies based on its strong and apparently differential staining in 
oesophageal epithelium. 
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 MOLECULAR BASIS OF HUMAN VISCERAL 
PAIN HYPERSENSITIVITY IN THE 
OESOPHAGUS: THE RELATIONSHIP OF 
SYMPTOMS TO MUCOSAL ASIC3 EXPRESSION 
 
 
3.1 INTRODUCTION 
Acid-sensing ion channels (ASICs) were introduced in Chapter 1 (1.5.2: Peripheral 
sensitisation) and the rationale for studying epithelial ASIC3 in Chapter 2. This 
chapter covers the systematic study of ASIC3 expression in mucosal biopsies in 
relation to GORD. 
 
3.1.1 Background 
 
3.1.1.1 ASIC3 
ASICs are members of the epithelial sodium channels/degenerin family, which is 
associated with neurotransmission
168
. ASIC3, previously known as DRASIC (dorsal 
root acid- sensing ion channel)
169
, is present in rodent CNS and in peripheral somatic 
sensory neurons such as those innervating the muscle and skin
51 170
. An earlier 
functional study demonstrated that ASIC3 is more closely associated with mechano-
transduction rather than acid sensing
48
. In this seminal study, it was shown that 
knockouts of ASIC3 mice exhibited reduced sensitivity to mechano-sensation 
(measured as the recorded number of spikes/per second) after von Frey/stretch 
stimulations, but crucially stimulation to mucosal receptors remained unchanged. 
These results highlighted the separation between epithelial and neuronal receptors in 
sensation. 
 
Although ASICs in sensory neurons function primarily as mechanosensors
171
 
48
, they 
have also been known to contribute to nociception accompanying tissue acidosis
169 172
. 
ASIC subunits can form H+ gated cation channels capable of acting as effective 
neuronal acid sensors within a wide pH range 
173 174
. Furthermore, NGF and serotonin 
3 
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(both of which are increased in mucosal inflammation) stimulate ASIC3 transcription 
in peripheral sensory neurones through direct interaction with the promoter region of 
the ASIC3 gene
175
 
176
. 
 
3.1.1.2 Distribution of ASIC3 in humans 
Human ASIC3 has been cloned from a foetal cDNA library 
177
 and testes
178
, and 
shows an 84% sequence identity with rat ASIC3 
169
. Human ASIC3 has been 
demonstrated in dorsal root ganglia
179
, sensory ganglia
177
 and in a variety of other 
tissues including bronchial cells, tracheal cells, human small airway epithelial cells
180
 
as well as the intestine
179
. 
 
3.1.1.3 The role of ASIC3 in acid-induced VPH 
The distribution and role of ASIC3 have been studied in acid-exposed and non-acid-
exposed regions of the GIT in experimental animals
48
 and, to a lesser extent, in 
humans
179
, the latter confirming up-regulation during inflammatory conditions. 
Specific to its role as an acid sensor are two experimental studies. Akiba, et al.
136
 used 
luminal CO2 to produce changes mimicking acid infusion. The use of an established 
ASIC3 inhibitor (amiloride derivative
181 182
) was shown to attenuate the hyperaemic 
response of the oesophagus to this stimulus
136
. ASIC3 was also noted to be present in 
rat epithelial cells, in particular stratum spinosum (prickle cells)
136
. The second study, 
conducted by Wultsh et al., explored the sensory role of ASIC3 in the presence of 
gastritis
183
. Using a rat model, acid (HCL) or saline was infused for 2 hours in the 
normal and inflamed stomachs (gastritis) of conscious rats. Activation of neurons in 
the nucleus of the tractus solitarii (NTS) of the brain stem was visualised by 
immunohistochemistry using c-Fos. Exposure of normal gastric mucosa to acid caused 
a three-fold increase in C-Fos activity compared to saline in wild-type rats
183
. 
Knockout of ASIC3 did not affect this observation. In the same model, using rats pre-
treated with iodoacetamide in drinking water for 7 days (to induce gastritis), the 41% 
increase in NTS c-Fos-positive neurons after acid infusion in the wild-type rats was 
absent in ASIC3 knockouts. Thus, ASIC3 appears to have a role in acid sensing in 
pathological conditions characterised by mucosal inflammation. 
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3.1.2 Rationale 
In Chapter 2, it was established that nerve fibres were absent within the human 
oesophageal epithelium. ASIC3, however, could be considered a promising epithelial 
biomarker based on the demonstration of varying intensity and distribution of sub-
cellular immunostaining. Given the acknowledged role of ASIC in acid and the 
damage sensing outlined above, it was reasonable to study ASIC3 in mucosal biopsies 
in this study. 
 
3.1.3 Aims  
The aims were to: 
1. Assess epithelial ASIC3 expression in mucosal biopsies of patients within the 
spectrum of GORD; 
2. Correlate the severity of common GORD symptoms with mucosal expression 
of ASIC3. 
 
 
3.2 SUBJECTS AND METHODS 
 
3.2.1 National research ethics approval 
This body of work was submitted in the same ethics application as the full-thickness 
oesophagus study (Chapter 2). The updating of the patient enrolment for this part was 
done via the UKCRN (United Kingdom Clinical Research Network), study reference 
number 4823 (https://portal.ukcrn.org.uk). 
 
3.2.2 Subjects 
Patients within or without the spectrum of GORD aged 18-60 years old, without other 
significant past medical histories, were recruited from those attending the Hermann 
Taylor endoscopy department of the Royal London Hospital.  
 
3.2.3  Inclusion and exclusion criteria 
Patients with conditions that could affect normal physiology on pain and reporting 
were excluded from the study. Specific inclusion and exclusion criteria were: 
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Inclusion criteria 
1. Male or female subjects aged 18−60 years (GI physiology and sensation could be 
different in those aged <18 or >60 years ); 
2. Main presenting complaint or symptomatic evidence of GORD; 
3. Patients undergoing investigation for anaemia, cancer surveillance or unexplained 
weight loss without acid-related symptoms volunteered as controls.  
Exclusion criteria 
1. The participants were required to speak English (as the study was dependent on 
the subjective reporting of pain thresholds and adverse effects, which could not be 
undertaken through an interpreter); 
2. Chronic serious systemic diseases (except acid-reflux related conditions) including 
cardiac, liver, renal, metabolic, malignancies, neurological or psychiatric as 
assessed by medical assessment/endoscopy admission clerking; 
3. Currently using recreational drugs or pain killers; 
4. Pregnancy due to higher incidence of physiological acid reflux in pregnant women 
and normal physiology not fully examined and appreciated; 
5. BMI (Body Mass Index) > 35.  
 
3.2.4 Patient recruitment process 
Participant information sheets were sent to the patients before their endoscopy 
appointment dates. Some patients called to express interest in participation prior to 
arrival, while others expressed interest on arrival at the endoscopy department. 
Patients who agreed to participate all consented to research at the same time as the 
routine clinical consent. Subsequently, they underwent a quick medical assessment 
(structured medical assessment) and completed questionnaires on symptom severity. 
They were reminded of the second (multi-modal) visit and contact details of the 
researcher if they were interested.  
 
3.2.5  Endoscopy and biopsy 
The subjects underwent routine standard trans-oral oesophagogastroduodenoscopy 
(OGD) using Olympus gastroscopes (GIF XQ 260 2.8mm channel, Olympus, 
Olympus Europa, Hamburg, Germany). Additional biopsies were obtained using tooth 
biopsy forceps (Captura biopsy forceps with a spike, 2.4mm, Cook Medical, Indiana, 
USA). Oesophageal biopsies were taken at a fixed position 3-5 cm above the lower 
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oesophageal sphincter (LOS). In patients with GORD, biopsies were taken between 
oesophageal erosions or away from actual erosions to obtain epithelium. Each patient 
contributed four biopsies for the research. Two biopsies were snap-frozen in liquid 
nitrogen and the remaining two immersed in formalin fixation for 24 hours at room 
temperature. Frozen samples were stored at -80 °C and the formalin-fixed samples 
processed by lab staff into anonymous paraffin-fixed cassettes and stored as such. Full 
protocols for fixation and tissue preparation were as described in Chapter 2, Appendix 
2.03. Protocols of the endoscopy unit in terms of safety and recovery were observed 
for all patients. 
 
3.2.6  Questionnaires 
A structured medical assessment was used as well as a validated questionnaire, 
developed and routinely used in the department, which was used to assess the type and 
severity of GORD symptoms. The six specific symptoms scored using VAS were 
adapted from ReQuest
TM
 (validated GORD) questionnaires 
184
 to quantify subjective 
symptom severity. The actual full protocol of ReQuest
TM
 questionnaires had to be 
filled in for four weeks, usually to monitor treatment progress, which was neither 
practical nor necessary for this study. Thus, we only used the ReQuest
TM
 scores (1-10) 
as a single ‘snapshot’ to assess current symptom severity, filled in during the visit by 
the patients. The ReQuest
TM
 questionnaire was used by kind permission of the author 
(Prof KD Bardhan). The six symptoms assessed were (copy of questionnaire available 
in Appendix 3.01): 
1. General feeling 
2. Acid complaints 
3. Upper abdominal/stomach complaints 
4. Lower abdominal/digestive complaints 
5. Nausea 
6. Sleep disturbances 
 
3.2.7  Multi-modal sensitivity tests 
A specifically commissioned catheter has been validated in previous studies in the 
human oesophagus (Figure 3.1)
15 185
. Training was provided at the University of Aalborg, 
Denmark with my collaborators, who were also responsible for inventing the instrument. 
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This training took place during my five-week attachment in Denmark from 6
th
 February 
to 4
th
 March 2007. All stimuli were repeated three times and stopped as soon as the 
subjects reached their pain threshold. This threshold was recorded.  
 
 
 
 
 
 
 
 
 
Figure 3.1: The oesophageal multi-modal catheter. (A) Schematic representation of 
the balloon of the multi-modal catheter. Thermal and mechanical stimulations were 
delivered via water perfusion and monitored for intra-balloon pressure monitor as 
well as with a temperature probe. The balloon is also equipped with impedance 
planimetry technology for estimating the cross-sectional area if desired
186
. (B) The 
balloon ex-vivo. 
 
Thermosensitivity: Cold and heat stimuli were given with a recirculation of 5ml of 
water in a polyurethane bag, which was in a tubing system primed with cold water. 
The probe had two perfusion channels attached to a manually controlled pump system, 
where water was infused into one channel and simultaneously sucked out of the other. 
Water temperature was maintained by the thermostatically controlled water bath 
maintained at 65°C. A thermal electrode was placed into the probe to record the 
temperature of water in the exit channel. As warm water was infused, the water 
temperature varied from 20-60°C, recorded in 10°C increments. For each infusion, the 
subjects rated sensation and pain on a visual analogue scale of (VAS) 1-10 (Appendix 
3.02).  
 
Mechano-sensitivity: Using the same balloon, water was infused at a fixed temperature 
of 38°C at an infusion rate of 10ml/minute until sensation was first felt (first constant 
sensation) and then to the maximum tolerated (maximum tolerated volume: pain felt). 
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The maximum volume was set at 25ml. Subjects were required to complete VAS 
scores for sensation and pain. 
 
Electrical Stimulation: The multi-modal catheter incorporates a metal bipolar ring 
electrode at its distal tip to deliver electrical stimuli. Thresholds to stimulation 
measured as intensity in mA, at which the subject first reported sensation and 
discomfort, were determined in a stepwise fashion, increasing the intensity of 
stimulation in increments of 2 mA on three separate occasions, from which mean 
threshold values were calculated. Patients were then asked to rate these sensations on 
a VAS. Discomfort was defined not as the maximal pain that could be tolerated, but 
rather as the level at which further stimulation would not be desirable. An electrical 
current was also applied via electrodes to the foot, to act as somatic control for the 
same protocol.  
 
3.2.7  Cellular analysis  
Detailed paraffin fixation, immunohistochemistry methods and sectioning were as 
described for the full-thickness oesophageal samples in Chapter 2 and Appendix 2.02-
2.06. From the paraffin fixation cassettes, 3-5 micron sections were cut using a 
microtome (Shandon Finese E+, ThermoFisher Scientific, Leicestershire UK), 
mounted on glass slides (VWR International, Leicestershire, UK) and incubated at 
37ºC in an oven before use. These sections were processed for H&E to characterise 
the presence or absence of oesophagitis, ulceration and other cellular changes such as 
metaplasia (Barrett’s oesophagus), as well as confirming that the biopsies were indeed 
of oesophageal squamous epithelium. Immunohistochemistry (IHC) using the ASIC3 
antibody (Abcam, Massachusetts USA) was performed based on the optimisation 
schedule from Chapter 2. Validation of this antibody in Western blotting was 
performed by the manufacturer (Appendix 3.03), while H&E was performed in a 
similar fashion to that outlined in Chapter 2 (Appendix 2.02-2.04.). 
 
3.2.8  Outcome measures 
ASIC3 immunostaining acted as the primary outcome measure. The results were 
expressed based on morphology and distribution of epithelial immuno reactivities 
carried out by two researchers (myself and Dr Andrew Hubball), with the slides 
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anonymised and blinded to their clinical details. H&E staining reporting was 
performed blind by a consultant pathologist with an interest in upper GI diseases (Dr 
Joanne Chin-Aleong). 
 
3.2.9  Data analysis 
The original sample size calculation was performed on the basis of projected results 
for TRPV1. The main analysis was intended to be a scatter graph of symptom scores 
vs. TRPV1, with a 95% confidence interval for correlation coefficient. This assumed a 
standard deviation of 10% estimated from data in a previous study 
187
. A total sample 
size of 48 patients or more would have to have 80% power to detect a significant 
correlation (r ≥ 0.8). Since there were no preceding data on epithelial ASIC3 in the 
human oesophagus, it was deemed reasonable to continue to use the calculation based 
on TRPV1, since this sample size also lay within a feasible range for recruitment.  
 
Softwares used for analysis were; Excel (Microsoft Corp, USA) and graph-pad prism 
(Graph-pad software Inc, California, USA). Tests for normality, median and inter-
quartile ranges were initially performed. Further comparisons of data were then 
performed using; Fisher exact test for analysis of ASIC3 features in different disease 
classification, Wilcoxon paired test for comparison of proportion of patients with 
ASIC3 features across 2 symptom-based groups, and Kuskal-Wallis test for 
comparison of symptom scores across 3 patient groups based on clinical classification.  
 
 
3.3  RESULTS 
 
3.3.1 Subjects  
Out of a total of 44 patients who consented to their involvement in the study, three sets 
of slides went missing in transition and five failed to satisfy the inclusion and 
exclusion criteria. The reasons were undisclosed or overlooked during consent, but 
were then found in medical records or discovered during the endoscopy itself (one 
with previous treated pancreatic cancer, severe diabetic neuropathy, discovery of 
upper GI mass, discovery gastric polyp and over the age limit with cardiac ischeamia). 
Thus, only 36 sets of samples from corresponding patients were analysed, 17 of which 
were female (mean age 42.5 years, range 19-59 years). 
  PhD Thesis 2010 
 
___________________________________________________________________________________ 
 
84 
 
3.3.2 Disease classification 
Patients referred without overt acid-related symptoms, and presenting complaints 
based on clinical details (referral letters and medical assessments), were classified as 
controls. Those with acid-related reflux were separated based on OGD findings to 
either the erosive oesophagitis (EO) or non-erosive reflux disease (NERD) group. As 
this last cohort did not have an objective measure from pH studies, they could 
represent both NERD as well as functional heartburn (FH). In total, of the 36 patients, 
14 were healthy controls, 18 NERD/FH and four EO. With modern treatment and the 
wide use of effective acid suppressant treatment, patients with erosions were rare.  
 
H&E analyses for the patients showed normal to mild inflammation in 34 slides. 
Moderate inflammation was found in two samples. No severe inflammation 
considered pathological was found. However, the aim was to assess mucosal sensation 
and epithelial receptors; therefore, biopsies were obtained away from areas of 
erosion/inflammation. As a result, the disease classification was based entirely on 
clinical symptoms/endoscopic findings and not histopathology.  
 
3.3.3 ASIC3 immunohistochemistry 
 
3.3.3.1  Distribution 
ASIC3 staining was present in the epithelium of most samples. Distribution, however, 
varied from the deep stratum basale to stratum spinosum, to the superficial luminal 
aspect. There were some samples with almost no staining. Interestingly, some samples 
exhibited a nucleated superficial layer of cells that looked almost like the stratum 
lucidum/corneum of the keratinised stratified squamous epithelium of the skin. 
However, since the oesophageal epithelium is non-keratinised and this layer was not 
previously described, this is simply referred to as the ‘luminal layer’.  
 
3.3.3.2  Morphology 
Most ASIC3 immunostaining was found surrounding the nuclei, termed ‘perinuclear’, 
in the stratum spinosum layer. However, within the stratum spinosum, which is the 
thickest layer of the epithelium, some staining was also noted to predominate on the 
cytoplasmic membrane of the cells (membrane-bound), giving the appearance of an 
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area free from staining between the basophilic nucleus and the brown (DAB) ASIC3 
stain. Membrane-bound staining tended to be located in the more superficial aspect of 
the stratum spinosum compared to perinuclear staining. 
 
3.3.3.3  Analysis 
The above description can be considered as four separate characteristics of ASIC3 
staining based on anatomical location and cellular morphology. These four features 
were assessed as present or absent, as detailed in table 3.1. 
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Characteristic Positive Negative 
 
Stratum Basale 
Basal layer (BL) 
 
 
 
Stratum Spinosum 
I) Perinuclear (PN) 
 
 
 
 
II) Membrane 
bound (MB) 
 
 
 
Stratum lucidum 
Luminal layer 
(LL) 
 
 
 
Table 3.1: 4 separate ASIC3 features for human oesophageal biopsies. For each 
feature, points were given as either 1=positive, 0=negative. Analysis was performed 
on the percentages of patients expressing particular features. 
 
3.3.4 Distribution of ASIC3 based on disease classification 
Based on the presence or absence of these characteristics, analysis was undertaken in 
respect of disease classification based on endoscopic and clinical findings (as 
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described in 3.3.2: Disease Classification) 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Stratum basale (basal
layer)
Stratum spinosum
perinuclear
Stratum spinosum
membrane-bound
Stratum lucidum (outer
layer)
Control
NERD/FH
EO
 
Figure 3.2: ASIC3 immunohistochemical characteristics in the controls, patients with 
NERD/FH and EO. The membrane-bound feature was statistically significant between 
patients with NERD/FH and EO, with p=0.028 for the Fisher exact test. 
 
3.3.5  Expression of ASIC3 based on histological evidence of inflammation 
As only two slides were considered to have moderate inflammation, compared to 34 
with normal to mild inflammation, no analyses were undertaken. 
 
3.3.6 Expression of ASIC3 based on symptom severity 
On the basis of dividing patients into two groups in line with their scores (<5 or ≥ 5), 
proportions with certain staining characteristics could be compared (Table: 3.2). 
Controls were included in symptom assessment, as many of the symptoms assessed 
were generic, including general feeling, sleep and nausea. It was important to identify 
if these features were markers for symptoms independent of inflammation or erosions. 
In general, all characteristics were seen with a greater prevalence in patients in the 
higher scoring group, i.e. more severe symptomatic group (symptoms < 5, median 
51.50% [34.05-79.47], symptoms ≥5, median 64.71% [35.39-86.61]. The three 
symptoms in particular, demonstrating the most consistent pattern of correlation, were 
acid symptoms, lower GI complaints and sleep complaints (Figure 3.3).  
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Symptoms Severity BL PN MB LL 
General 
Feeling 
<5  
≥5  
13/16 (81%) 
16/20 (80%) 
11/16 (69%) 
18/20 (90%) 
8/16 (50%) 
9/20 (45%)  
5/16 (31%) 
4/20 (20%) 
Acid 
complaints 
<5 
≥5 
16/20 (80%) 
14/16 (88%) 
13/20 (65%) 
16/16 (100%) 
8/20 (40%) 
8/16 (50%) 
5/20 (25%) 
4/16 (25%) 
Upper GI 
discomfort 
<5 
≥5 
16/19 (84%) 
13/17 (76%) 
15/19 (79%) 
14/17 (82%) 
7/19 (37%)  
9/17 (53%) 
5/19 (26%) 
4/17 (24%) 
Lower GI 
discomfort 
<5 
≥5 
17/22 (77%) 
13/14 (93%) 
18/22 (82%)  
11/14(79%) 
9/22 (41%) 
7/14(50%) 
5/22 (23%) 
4/14(31%) 
Nausea  <5 
≥5 
21/26 (81%) 
9/10 (90%) 
20/26 (77%) 
9/10 (90%) 
12/26(50%) 
4/10 (40%) 
7/26 (27%) 
2/10 (20%) 
Sleep 
disturbances 
<5 
≥5 
12/15 (80%) 
18/21 (86%) 
11/15 (73%) 
18/21 (86%) 
6/15 (40%) 
10/21(48%) 
3/15 (20%) 
6/21 (29%) 
 
Table 3.2: Percentage of patients with symptom scores (<5 or ≥ 5), with each ASIC3 
staining characteristic. Key: BL-basal layer, PN-perinuclear, MB-membrane bound, 
LL-luminal layer. Difference between the two symptom severity groups, for all ASIC3 
characteristics. 
 
 
0%
20%
40%
60%
80%
100%
120%
BL PN MB LL BL PN MB LL BL PN MB LL
          Acid symptoms          Lower GI complaints          Sleep problems      
VAS <5
VAS ≥5
 
Figure 3.3: Comparison of ASIC3 staining characteristics for symptoms with the most 
differences between two symptom severity groups. 
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3.3.7 Symptom severity based on disease classification 
A VAS assessment of symptom severity demonstrated that symptoms were, in 
general, worse in NERD/FH patients for all six symptoms assessed (Median VAS:  
controls-1, NERD/FH-5, EO-1. NERD/FH compared to EO, p<0.05, and control 
patients, Dunn’s multiple comparison test, p<0.001) (Figure 3.4). Although the 
controls were referred for non-acid-related symptoms, it was interesting that their 
scores were not consistently 1 when questioned (out of 14 controls, 10 scored the 
minimum 1 for both ‘acid’ or ‘upper GI complaints’. Also, a number of generic 
symptoms were assessed).  
 
   
    
 
 
 
 
 
   
    
A       B 
Figure 3.4: (A) VAS scores of six individual symptoms based on ReQuest
TM
 for 
controls, patients with NERD/FH and EO. B) Pooled symptom severity scores for the 
same three groups of patients, Kruskal-Wallis=0.0003, Dunn’s multiple comparison 
test, control vs. NERD/FH p<0.001 and NERD/FH vs. EO p<0.05. 
 
3.3.8 Multimodal sensitivity testing 
Despite successful piloting in five healthy volunteers, out of the patients who had 
consented to oesophageal biopsies, only three actually underwent multi-modal 
oesophageal sensitivity testing and one failed intubation. Although oral intubation of 
the catheter was successful in healthy volunteers, it was not acceptable to most 
patients, especially without the use of local anaesthetic spray. Furthermore, intubation 
of the semi-rigid multimodal catheter was almost akin to oral intubation with a 
gastroscope, without the benefit of direct vision and a navigation system. 
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3.4 DISCUSSION 
 
3.4.1 Summary of the findings 
Four separate ASIC3 immunostaining characteristics were determined in the human 
oesophageal mucosal biopsies based on morphology and anatomical distribution, 
namely basal cell staining, stratum spinosum – perinuclear or membrane bound – and 
luminal layer staining. These four features were generally lowest in the controls and 
highest in NERD patients. EO patients expressed maximal basal cell staining as well 
as perinuclear appearance in the stratum spinosum. The more superficial features were 
not detected in the EO cohort, perhaps because of erosions. Patients with higher 
symptom severity were also more likely to exhibit evidence of all four ASIC3 
characteristics. 
 
3.4.2 Limitations 
The patients were classified based on clinical assessments and clinical endoscopic 
findings. Patients considered as controls did not have symptoms of acid as their main 
presenting problems, yet their symptom scores were not consistently at the minimum 
of 1. Perhaps occasional acid reflux occurred even in healthy subjects and some of the 
symptoms assessed were very generic (e.g. general feeling, sleep problems, lower GI 
discomfort). It indicated the tool is sensitive to normal population complaints.  I 
thought it was important to retain the study’s classification based on the participants’ 
presenting complaints (rather than to reassign them based on symptom scores) because 
in the general healthy population, individuals do experience acid reflux and upper GI 
pain. Therefore, this control group, although symptomatic when questioned in detail, 
did not feel their acid-related symptoms were particularly problematic, and were thus 
not representative of FH or NERD. Similarly, being referred for an OGD, they could 
not be representative of an entirely ‘normal’ population either. The observed effect of 
the results, therefore, would likely be greater if NERD/FH data were compared to 
completely healthy volunteers rather than patient controls. 
 
Patients with acid-related presenting complaints as the reason for OGD were 
considered to be EO if they had evidence of erosions on the endoscopy. The remaining 
patients were classified as NERD/FH based on symptoms and the endoscopy (no 
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erosions). Ideally, subjects needed to undergo pH monitoring to differentiate NERD 
from FH. However, this would have involved two additional visits on top of the 
endoscopy and multi-modal oesophageal stimulation visit – this would have impinged 
on the GI physiology department’s clinical service provision, which was already in 
high demand. Moreover, the aim of the study was mainly to correlate ASIC3 (or other 
markers) with the development and severity of symptoms rather than to another 
disease-based biomarker.  
 
Smoking should also be added as an exclusion criterion. Smoking is well-known to 
cause and contribute to acid reflux
188
. Smokers therefore are likely to suffer from 
chronic acid reflux
189
 and may have changes in receptor expression in the epithelium. 
These changes are likely to be non-representative of healthy sensation. In addition, 
smoking is also likely to affect the cellular development and morphology of the 
oesophageal epithelium itself. For example, smoking has been known to contribute to 
development of Barrett’s oesophagus as well as oesophageal adeconocarcinoma190 191.  
 
Irrespective of whether patients were in or outside the GORD spectrum, we correlated 
symptoms to the expression of ASIC3. On the basis that symptoms might also be 
deemed more clinically relevant to real-life patients, the six symptoms chosen were 
adapted from a validated GORD questionnaire (ReQuest
TM
 questionnaire), which has 
previously proven to be a useful tool for monitoring the progress of GORD treatment 
including newly available acid suppressant treatment
192
. We originally planned to 
have an objective and comprehensive multi-modal oesophageal stimulation visit to 
profile the subjects’ oesophageal sensitivities in detail, but this was not possible for 
the reasons mentioned above.  
 
The next main limitation was the rudimentary and essentially qualitative (binary) 
methods used to describe ASIC3 distribution. Since ASIC3 is present in all groups to 
some degree, any future predictive model would require a more detailed scoring 
system based on ASIC3 quantitation using either automated microscopic 
quantification methods of analysis on the immunohistochemistry, or immunoblotting 
of mucosal biopsy samples. With adequate controls and appropriate equipment, 
quantification methods using digital computer assisted method had proved reliable
193
, 
consistent and reduced observer bias
194
 . Automated quantification is recommended 
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for more complicated analysis where traditional methods may have limitations
195
.  The 
density of each morphology sub-type in the relevant layer should be better quantified. 
As such, the current findings of increased ASIC3 with increasing symptoms must be 
considered speculative at best. In future, perhaps final patient scores might be plotted 
against the severity of symptoms and extrapolated to provide a correlation line that has 
the potential to be developed into a predictive guide to symptom severity.  
 
The final limitation is the lack of any clear understanding of the significance of 
different morphological characteristics of ASIC3 staining patterns. Broadly, the results 
show that there is more ASIC3 in general in patients with GORD than for the controls, 
and its distribution changes slightly. Both observations could have been greatly 
supported by first qualitative demonstration of an appropriate mRNA transcript (by 
PCR) and the former by quantitative data obtained from alternative methods, 
especially qRT-PCR. It has been noted that the current theory of retrograde neuronal 
transportation suggests that the up-regulation of protein synthesis for neuronal 
proteins occurs in the DRG and that this could thus not be captured in epithelial 
biopsies. However, this is not true of epithelial proteins, where it is likely that protein 
synthesis occurs within the epithelial granular layer, where mitotic activity is high and 
continues as these cells mature towards the luminal surface. RT-qPCR will certainly 
have a role in exploring the mechanisms of epithelial protein up-regulation in a future 
study.  
 
3.4.3 Clinical relevance 
 
3.4.3.1 ASIC3 as biomarker of GORD 
Although the preliminary results are insufficient to recommend ASIC3 as a biomarker 
at the current time, the quest to assert whether ASIC3 could function as a biomarker of 
peripheral sensitisation remains. The only statistically significant results were the 
‘membrane bound’ appearance of ASIC3 being significantly different between the 
groups. This was limited by the small numbers and difficult to comment. More 
importantly, was the pattern being established in the other morphology sub-groups 
seemed to indicate acid exposure or disease sub-types were important to trigger 
ASIC3 expression in the epithelium; increasing from controls to EO. As mentioned 
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above in 3.4.2, we hope to look for ASIC3 as a marker for symptom severity, not as 
another disease marker of EO, NERD or FH.  I speculate that the stratum spinosum 
‘membrane-bound’ appearance to be clinically more important as hinted by the 
statistical significance (despite small numbers), as well as it likely to represent the 
physiologically active morphology of ASIC3 important in luminal sensation (being 
found in the more superficial layer of epithelium and on the epithelial cell membrane 
itself).   
 
The role of ASIC3 has been attributed mainly to sensation
50
, but the experimental use 
of an ASIC3 inhibitor has also been shown to reduce hyperaemic
136
 response to acid. 
ASIC3 is not unique in this role; TRPV1 is also associated with inflammation, with 
several studies demonstrating clearly that TRPV1 activation leads to neurogenic
196
 
161
 
and epithelial
197 198
 inflammatory mediator release, e.g. Substance-P, CGRP and PAF, 
which form an important peripheral sensitisation (PS) mechanism
160 161
. Neither a 
cause nor an effect of this relationship has been established for ASICs, but they might 
function similarly. In keeping with this hypothesis is the finding that NERD patients 
had more ASIC3 characteristics. NERD patients will present with the highest 
symptomatology and most consistent VPH to a variety of stimuli including acid
158 159
. 
However, NERD patients by definition have minimal physical evidence of 
inflammation. Therefore, it is unlikely that inflammation either leads to, or is caused 
by, increased ASIC3 expression; rather, ASIC3, by some way mediating signals from 
acid exposure of the epithelium, may lead to neuronal sensitisation in the absence of 
any major effect on inflammation. 
 
3.4.3.2 ASIC3 and symptoms 
The percentage of patients with certain ASIC3 characteristics increased with the 
severity of symptom profiles. An increase in symptom severity was associated with an 
increase in all four ASIC3 features. This association was more pronounced for three 
symptoms: acid complaints, sleep disturbance and lower GI discomfort (also defined 
as ‘indigestion’ in the questionnaire). 
 
The first association is in keeping with the general hypothesis of ASIC3 as an acid 
sensory and a nociceptive receptor in published studies
136 183
. The associations with 
sleep disturbance and indigestion are more difficult to explain, as these are more 
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general symptoms and we postulate that they could relate to the role of ASIC3 in 
mechano-transduction
48
. Page, et al.
48
 established a clear relationship between the 
expression of oesophageal ASIC3 and increased action potentials leading to changes 
in contractility and motility. An increase in ASIC3 in GORD symptoms may be 
responsible for altered motility; this, aside from the sensation of altered pH per se, 
could contribute to further symptoms. An increase in the firing of action potential 
resulting from an increase in ASIC3
48
 could also be interpreted as a negative feedback 
mechanism providing distal visceral relaxation and promoting better gastric emptying, 
in order to relieve intra-gastric pressure and reduce reflux. 
 
3.4.3.3 Modulation of ASIC3 as a potential treatment for GORD symptoms 
Although the use of an ASIC inhibitor has been efficacious in reducing animal 
hyperaemic
136
 responses to acid infusion in the rat oesophagus, the action of ASIC3 in 
gut motility and mechano-sensation need to be explored further before translation into 
human therapy. Clinical utility of the ASIC3 receptor antagonist will have to 
presumably clear the same hurdles as TRPV1 in terms of ubiquitous expression and 
thus adverse events and generic side effects. Novel and experimental ASIC3 
modulating agents will be discussed in Chapter 6. 
 
 
3.6 CONCLUSIONS 
This study showed that epithelial ASIC3 in biopsy samples is present, but epithelial 
ASIC3 characteristics have weak association with clinical classification. Similarly, 
there was a significant but modest association between ASIC3 characteristics with an 
increase in symptom severity. Although there were several limitations in this study, 
overall it highlighted some interesting ASIC3 cellular expression, important clinical 
associations, relevance of epithelial biomarker and feasibility. Future studies are 
required to determine whether ASIC3 is a practical/useful marker of GORD 
symptoms. 
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HUMAN MODEL OF VISCERAL PAIN 
HYPERSENSITIVITY: THE MODEL, 
REPRODUCIBILITY AND VARIABILITY 
 
 
4.1 INTRODUCTION 
 
4.1.1  The need for a VPH model  
Visceral pain hypersensitivity (VPH) is a concept that has evolved rapidly over the 
last few decades and is considered to be an important patho-physiological mechanism 
for the development of visceral pain in functional gastro-intestinal disorders (FGIDs). 
However, studies in patients with established FGIDs make it difficult to tease out the 
individual mechanisms involved in the development of VPH, as quite often these 
patients present with multiple factors that may have an impact on our understanding of 
VPH. These include psychological and physiological factors, which are much easier to 
control for in healthy volunteer studies. Animal VPH models have leaned away from 
the oesophagus to observe pathophysiological changes in other organs in response to 
experimental induction of injury, inflammation or both
74 199
. In man, these regions, 
e.g. the colon and rectum, have been the subject of extensive studies in patients with 
inflammatory disease states, such as ulcerative colitis, and in functional disorders 
characterised by hypersensitivity, such as IBS
200
, but have not been well-modelled in 
healthy volunteers
201
 
202
 for reasons of accessibility/acceptability. 
For the above reasons, work conducted in the department has focused on 
understanding both the causes of VPH and the factors that modulate it. This has been 
performed by developing and using a healthy volunteer model of acid-induced VPH to 
explore hypersensitivity in human oesophagi. However, for this model to be accepted 
as a standard, it is important to demonstrate that it is reproducible. This is particularly 
relevant when a particular model is considered for use in pharmacological studies. 
Prior to the start of my interventional study using this VPH model, I have analysed the 
results of previous studies to determine its reproducibility. For the purpose of the rest 
4 
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of the chapter, and to make it easier to link to subsequent chapters, VPH in the 
oesophagus will be referred to as ‘oesophageal’ visceral pain hypersensitivity (VPH).  
 
4.1.2  The human VPH model  
In the human oesophagus, common clinical conditions where VPH is believed to play 
an important role include non-erosive reflux disease (NERD) and functional heartburn 
(FH) (refer to Chapter 1). A human model using acid perfusion in the oesophagus to 
induce VPH in healthy volunteers was developed in the department. This was a robust 
model of human oesophageal sensitisation using acid infusion in the distal 
oesophagus, demonstrating the induction of pain hypersensitivity both in the distal 
acid exposed region (primary hyperalgesia),  the proximal non-acid exposed 
oesophagus and in the area of somatic referral on the anterior chest wall (secondary 
hyperalgesia) 
74
 (Chapter 1: 1.5.4: Human models of peripheral and central 
sensitisation). This secondary hyperalgesia is attenuated by Prostaglandin E2 receptor-
1 (EP-1) receptor antagonism 
203
, and both can be prevented and reversed with 
Ketamine, a N-Methyl D-Aspartate (NMDA) receptor antagonist 
75
, suggesting that 
central sensitisation (CS) is an important mechanism for the development of 
secondary hyperalgesia in this model. Indeed, cerebral cortical responses to this 
sensitisation model have now also been studied
204
, which demonstrate a reduction in 
the latency of these potentials after oesophageal acid infusion – suggesting 
sensitisation of afferent pathways. This model has been used extensively in many 
studies including drug trials
76 205 206
. 
 
4.1.3  Aims 
The first aim was to explore the reproducibility and variability of sensitisation in the 
model of acid-induced oesophageal hypersensitivity, through a retrospective analysis 
of departmental studies. Secondary aims were to identify limiting factors within the 
model and ways to overcome these problems. 
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4.2 SUBJECTS AND METHODS 
 
4.2.1 Subjects 
As some subjects participated in more than one study, 57 volunteers contributed to 85 
separate ‘infusions’. These studies were carried out between 2002 and 2006. These 57 
healthy volunteers (age range 20-58 years old, but due to a strict coding system, sex 
distribution could not be determined for pooled data) were from previous studies 
performed in GI Sciences at Manchester University.  
 
4.2.2 Methodology 
A total of six studies were included – five drug trials and one physiological study. The 
data collected were taken from the placebo and ‘screening’ arms of these drug and 
physiological studies, which were conducted by two main researchers. Screening 
studies were performed in two drug trials to identify sensitisers to acid infusion before 
randomisation. The importance of introducing a screening visit is discussed further in 
section 4.4: Discussion. The results of these studies regarding the effects of specific 
drugs on the model have been published previously
76 205 206
 (Table 4.1). I analysed the 
data retrospectively from these studies. 
 
4.2.3  Acid Infusion and Electrical Stimulation Model 
The human oesophageal VPH model is a validated model involving the infusion of 
physiological HCl (0.15M) via a naso-oesophageal tube to the distal oesophagus. This 
acid infusion lasted for 30 minutes. Baseline pain thresholds (PTs) to electrical 
stimulation in the oesophagus were measured in the proximal as well as distal 
oesophagus before and after acid infusion. The timing of post-acid electrical 
stimulation varied from study to study (Table 2.1). The electrical stimuli were 
delivered via electrical simulation catheter (with proximal and distal bipolar rings) at a 
frequency of 0.3 Hz, 500microseconds duration; intensity 0-100mA. Further technical 
details and equipment used for this model are described in greater detail in Chapter 5 
where they was used in a drug study (Section 5.2.5 and 5.2.6). 
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Intervention used in the 
studies 
Timing of PT 
measurements post-acid 
Number of 
Subjects 
Visit type 
1. Ketamine
76
 TI, T30, T60, T90, T120 13 Placebo 
2. Paracoxib
205
 TI, T60, T120, T180 6 Placebo 
3. Valdecoxib
205
 TI, T30, T60, T90 10 Placebo 
4. Neurokinin-1 receptor 
antagonist
206
 
T30, T60, T90, T120, 
T150 
9 Placebo 
5. Glycine antagonist TI, T30, T60, T90, T120 17 Placebo 
Screening 
6. ANS physiological 
characterisation 
TI, T30, T60, T90, T120 13 Screening 
 
Table 4.1: Recruitment of subjects from six different studies involving 85 separate 
distal oesophageal acid infusions (TI =immediately, T30=30 minutes, T60=60 
minutes, T90=90 minutes, T120=120 minutes, T150=150 minutes T180=180 minutes, 
all calculated from after completion of acid infusion) 
 
4.2.4 Statistics 
Only data from electrical stimulation of the proximal oesophagus after distal 
oesophageal acidification were included in the analysis, as these were most relevant to 
my studies. Raw data from the different studies were compiled and analysed. These 
compilations and raw data analyses were performed using Excel (Microsoft Corp, 
USA), SPSS (IBM Corp, New York, USA) and Stata (Stata Corp LP Texas USA). 
The methods used included tests for normality, means (with 95% CI) and medians 
(with inter-quartile ranges). For the main comparisons of maintenance of sensitisation 
across experimental time points (4.3.2: Time Effects), the results were analysed with a 
linear mixed model with ‘change in PT’ as an outcome, along with adjustments made 
for repeated measurements per person per study (GLLAMM command in Stata). For 
the sub-analysis looking at the order of visits, p value and difference in means were 
calculated from longitudinal regression, which also controlled for the same individuals 
and randomisation allocation. Placebo effect analysis was performed similar to order 
effect, controlling for the same individuals only. 
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4.3 RESULTS 
 
4.3.1 Threshold of sensitisation 
In the pooled data from the six studies, distal oesophageal acidification resulted in a 
fall in PTs at all time intervals in the proximal oesophagus post-acid infusion. The 
average change in PT after an infusion was a reduction of 7.4mA (-8.4 to –6.4 
p<0.001). Individuals with both absent and exaggerated sensitisation to acid were 
noted. A 6mA decrease was used in most studies to define sensitisation to acid 
infusion, and at this threshold analyses at just 60 minutes after acid (T60 being the 
consistent time point used in all studies) sensitisation were noted in 74% of infusions 
(63 out of 85 separate acid infusions). The use of 6mA in the early studies was 
arbitrary. However, looking at the different time points, variations in the number of 
subjects who sensitised were noted when different thresholds were used to define 
sensitisation in this model (Table 4.2).  
 
PT threshold Percentage sensitisers at all time points 
5mA 73.3% 
6mA 69.8% 
7mA 59.1% 
 
Table 4.2: The magnitude of ‘change in PT’ in the proximal oesophagus to define 
sensitisation after distal oesophageal acid infusion and the corresponding percentages 
of participants who sensitised. 
 
 
4.3.2 Time effects 
 
There were no statistically significant differences in the change in PT from 30 minutes 
to 120 minutes after acid infusion (Figure 4.1 and Table 4.3).  
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Figure 4.1: The drop in PT and its maintenance in the proximal oesophagus after 
distal oesophageal acid infusion. Compared to the baseline, the drop in PT across all 
time points was significant. Using linear mixed model with ‘change in PT’ as an 
outcome adjustments made for repeated measures per person per study, p<0.001. The 
main bar line represents mean, with 95% CI within the main box. 
 
 
 
Reduction in PT  Mean (95% CI) p-value 
30 mins -7.4(-8.4 to -6.3)mA <0.001 
Difference between 60 mins and 30 mins -0.4(-1.5 to 0.7)mA 0.482 
Difference between 90 mins and 30 mins 0.3(-0.8 to 1.5)mA 0.577 
Difference between 120 mins and 30 mins 0.0(-1.1 to 1.2)mA 0.963 
 
Table 4.3: The reduction in PTs at different time points post acid infusion 
(comparison of PT at 30 minutes was in relation to the baseline). 
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4.3.3 Placebo effect 
Comparing the screening visit with the placebo visit, the placebo effect is present, as 
demonstrated by the attenuation in sensitisation (+5.4mA; CI 2.8mA to 7.9mA; 
p<0.001). Again, this comparison was possible in one study only, which had both a 
screening visit as well as a placebo visit (Study 5). However, since the ‘screening’ 
visit took place prior to randomisation, effectively it was always performed prior to 
the placebo visit; hence, it is important to determine whether the observed differences 
in PT during the placebo visit in comparison to the screening visit were truly reflective 
of the placebo effect or related to order effects (Figure:4.2) 
 
 
  
   A      B 
Figure 4.2: (A) Absolute PT during screening and placebo visits in the proximal 
oesophagus; note baseline PT 35- 38mA. (B) The ‘change in PT’ in the proximal 
oesophagus after distal oesophageal acidification in the placebo visit compared to the 
screening visit was p<0.001 for all time points, using longitudinal regression 
controlling for same individuals. Main bar was mean value with 95% CI in the box. 
Both these charts are from a single study with placebo and screening visits. N=17. 
 
4.3.4. Order Effect 
 
Study 5, with 17 subjects (age 20-49 years, 8 males), produced information on the 
order of visits, and a screening visit was performed. Comparable numbers of subjects 
were subsequently randomised to either drug or placebo for the trial. These visits in 
the trial post randomisation were classed as visit 1 and visit 2. The average absolute 
PT for all time points in visit 2 (including baseline) was 6.8mA (95%CI: 3.1mA to 
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10.4 mA; p<0.001) higher than visit 1 (Figure 4.3). However, using the linear mixed 
model with a ‘reduction in PT’ as an outcome, there was no statistically significant 
difference in the change in PT after acid compared to the baseline between visit 1 and 
visit 2. Therefore, although absolute PTs increased with the second visit, the 
magnitude of change in PT remained the same for all time points (Figure 4.4). 
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Figure 4.3: The absolute PTs in the proximal oesophagus in the first  compared to the 
second post-randomisation visit, p<0.001 for all time points using longitudinal 
regression which controlled for the same individuals and randomisation allocation. 
Main bar was mean with 95% CI within the main box. N=17.  
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Figure 4.4: The ‘change in PT’ in the proximal oesophagus after distal oesophageal 
acidification in the first and second post-randomisation visits at all-time points, 
p=0.221. P was based on longitudinal regression which controlled for the same 
individuals and randomisation allocation. Main bar was mean with 95% CI within the 
main box. 
 
 
4.4 DISCUSSION 
The traditional definition or threshold of sensitisation was set between 5 to 7mA and 
varied between studies. This threshold range was originally set arbitrarily, but thought 
to be clinically significant. Now, with the benefit of more studies completed using this 
model, I was in a better position to review and identify a more precise threshold. From 
one of the studies with absolute values available for both the screening and placebo 
visits, the data confirmed that the mean baseline pain threshold (PT) in the proximal 
oesophagus during electrical simulation was 35mA for the screening visit and 38 mA 
for the placebo visit. A drop in PT of 5-7mA after acid sensitisation corresponded to a 
change of roughly 13-20% compared to mean baseline PT (prior to acid sensitisation). 
Ideally, selecting a higher threshold would ensure more significant change, but that 
had to be balanced with a realistic threshold to capture the majority of the population. 
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If the magnitude of sensitisation was defined as a reduction in pain threshold of 6mA, 
then sensitisation occurred in 70% of participants for all time points. Increasing this to 
7mA dropped sensitisation to 59% of the study population. Taking these two factors 
into account, 6mA is an optimum threshold for representing a significant clinical 
change, and it still captures more than two-thirds of the population. 
 
From the data, there seemed to be a wide variation in the degree of sensitisation, and 
up to one-quarter of the volunteers in the general population did not sensitise. 
However, in those who did, sensitisation was shown to be maintained for up to 120 
minutes after acid infusion. Furthermore, there did not seem to be significant changes 
between time points within these 120 minutes. Future studies could shorten the post 
acid stimulation time points to two events. In most studies investigating the effect of 
pharmacological and non-pharmacological intervention to influence sensitisation, non-
sensitisers would not be useful recruits. Therefore, we learnt that an initial screening 
visit is necessary to exclude these non-sensitisers. The ideal study model for studies 
intending to use this model would use a crossover method, allowing a suitable period 
of washout time depending on the half-life of the drug used. Analysis of results using 
crossover design would allow pairing of the same subject, avoiding the need for case 
control or matching in the case of parallel design. With a wide variation in the 
distribution of data, case control or parallel design would require a high number of 
subjects. However, one disadvantage of the crossover design which requires an 
additional screening visit is that it would require the participant to attend multiple 
visits. Therefore, we need to examine the effects of multiple visits and acid infusion 
on this model, especially after the mandatory screening visit. 
 
In one of the studies above, a screening visit was introduced. In this study, I examined 
PT and sensitisation in the two visits post-randomisation, where they were either 
subjected to a placebo or drug to explore if the sensitisation and robustness of this 
model would last up to the third visit. Although there seemed to be a consistently 
higher absolute PT for the later visit compared to the earlier one across all time points, 
the degree of sensitisation (defined as change in PT) was maintained for up to 120 
minutes (Figure: 4.4). This further strengthens the argument that a crossover study 
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design is robust, as multiple visits did not seem to diminish the sensitising effects of 
distal acid infusion.  
 
It is good practice to have a placebo arm in any interventional studies, including drug 
studies. In most interventional studies, the placebo effect is present. In drug studies 
using this model, we noted a significant placebo effect compared to the screening 
visit. Therefore, for an intervention to be considered effective, it has to exert an effect 
above that of the placebo, as order effects can occur. As already discussed, there was 
no change in the degree of sensitisation between visits post-randomisation. However, 
although it was possible for me to study the order effect between the screening and all 
the subsequent visits, since either a drug or placebo had been introduced post-
randomisation, therefore, comparison of the order effects between these visits would 
not be valid. Order effects should be best studied in a prospective study involving 
multiple visits (3 or more) controlling for all other factors without introduction of drug 
or placebo. Below is a table summarising all of the factors influencing sensitisation 
(Table 4.3). 
 
Influencing factor(s)  Observed effect(s) Recommendation(s) 
Definition of 
sensitisation threshold 
PT drop of 6mA represented 
a change of up to 20% in 
PT. It also captured almost 
70% of the population 
A sensitisation threshold of 
6mA to be used 
consistently 
Sensitisation does not 
occur in everyone  
70% sensitised across all 
time points at 6mA 
An initial screening visit to 
rule out non-sensitisers for 
drug studies 
Variation in magnitude 
of sensitisation 
Wide variation existed 
within population 
Crossover model, where 
volunteers will act as their 
own control group; in 
parallel group, use matched 
population or larger sample 
size will be required 
Time effect Sensitisation lasted up to 
120 minutes and maintained 
Duration of study and 
protocol could be 
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at 4 separate time points; 30, 
60, 90 and 120 minutes post 
acid infusion 
simplified to less than 120 
minutes and less time 
points 
Placebo effect Placebo effect detected Placebo control group must 
be used 
Order effect Increase in absolute PT after 
visit 1, but ‘change’ in PT 
not affected  
To analyse results on 
‘change’ in PT  
 
Table 4.4: Summary of potential limiting factors on the model, how they influence the 
model and recommended solutions. 
 
 
4.4 CONCLUSIONS 
Distal oesophageal acidification within this VPH model induced a reduction in PT in 
the proximal oesophagus in the majority of subjects (up to three-quarters), and the 
magnitude of sensitisation remained comparable for studies using multiple visits. 
Limiting factors within this model were identified and provided appropriate controls 
were taken (the introduction of a mandatory screening visit, placebo controlled arm, 
cross-over study design), this is a robust model for human studies of pharmacological 
and non-pharmacological modulation of human oesophageal acid induced VPH. Using 
findings from this experience and the model, we designed and explored the effect of 
Pregabalin in influencing acid-induced oesophageal VPH. 
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PREGABALIN PREVENTS THE DEVELOPMENT 
OF VISCERAL PAIN HYPERSENSITIVITY IN A 
MODEL OF OESOPHAGEAL ACID-INDUCED 
SENSITISATION IN HEALTHY VOLUNTEERS 
 
 
5.1 INTRODUCTION 
 
5.1.1 Background 
Gastro-oesophageal reflux disease (GORD) causes symptoms that can interfere with 
quality of life. It is a very common disorder, with 20–44% of Western people 
experiencing GORD symptoms at least once a month and 20% weekly
207
 
208
. GORD 
can be divided on the basis of endoscopic findings into erosive oesophagitis (EO) and 
non-erosive reflux disease (NERD)
209
. Other patients are defined as having functional 
heartburn (FH) when symptoms occur in the absence of abnormal acid exposure. 
Studies of acid exposure across the GORD spectrum have revealed an increasing 
prevalence of abnormal oesophageal acid exposure times, as defined by 24-hour pH 
monitoring while one progresses from FH and NERD through to EO
210 211
. This 
suggests that a factor other than acid reflux must be responsible for symptom 
generation in patients with NERD and FH 
212
. It is proposed that visceral pain 
hypersensitivity (VPH) is more common in patients with NERD and FH in 
comparison to EO and may cause symptoms in response to either physiological 
amounts of acid reflux or other luminal stimuli
213
 
214
. The VPH mechanism is unclear 
but involves (amongst other potential mechanisms) the dilatation of epithelial 
intercellular spaces
98
 and exposure of sub-epithelial nerves to acid
215 216
. This leads to 
the sensitisation of peripheral afferent nerves (peripheral sensitisation (PS)) and spinal 
dorsal horn neurons
77
 (central sensitisation (CS)) . Once CS is established, it can 
continue to potentiate pain after initial peripheral stimulus is discontinued.  
 
In addition to the above mentioned VPH mechanisms, psychological stress can also 
increase sensitivity to acid
217
 as well as exacerbate symptoms of GORD
218
. 
Relaxation, on the other hand, reduces pain during experimental oesophageal acid 
exposure
219
. Furthermore, stress has a direct effect on the autonomic nervous system 
5 
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(ANS), and there is recent preliminary evidence that acid exposure in the oesophagus 
alters the ANS profile differently in healthy subjects more susceptible to developing 
VPH compared to those who are more resistant
93
 
220
. However, the roles of stress and 
ANS in influencing the effectiveness of treatment for VPH are not known. 
 
A model in which the infusion of acid in the distal oesophagus induces sensitisation at 
the site of acid infusion (primary hyperalgesia), as well as in the proximal oesophagus 
(secondary hyperalgesia) due to PS and CS, respectively, has been described 
previously 
77 203 221
. Interestingly, anxiety induction exacerbates secondary 
hyperalgesia in this model. Furthermore, this model has been used to study the effects 
of various drugs on VPH
75 203 205 206
. For instance, Ketamine, an N-methyl D-Aspartate 
(NMDA) receptor antagonist, was effective in both preventing and reducing secondary 
hyperalgesia induced by experimental acid infusion
75
. However, Ketamine has 
considerable central side effects and requires intra-muscular or intravenous 
administration, making it impractical for routine use in practice. 
 
Pregabalin is a specific ligand of alpha-2-delta type 1 and 2 subunits of voltage gated 
calcium channels
222
, which can be given orally and act centrally. Pregabalin is 
structurally related to GABA but does not interact with GABA
223
 or NMDA 
receptors
224
; however, it reduces pain modulators including substance P
225
 and 
glutamate in the brain
224
. It is a gabapentinoid-like gabapentin, but has more 
predictable pharmacological effects and achieves therapeutic outcomes at lower doses, 
thereby reducing dose-related side effects. It is effective in non-inflammatory somatic 
pain including neuropathic pain
226
 and pain associated with diabetic neuropathy
227 228
 
and fibromyalgia
229
 
230 231
. Recently, it has been demonstrated that Pregabalin 
increases pain thresholds to rectal distension in patients with irritable bowel syndrome 
(IBS) 
232
.  
 
5.1.2 Aims 
The aim of this study was to determine the effect of Pregabalin on reducing acid-
induced oesophageal secondary hyperalgesia (compared to the placebo) in this model 
(primary outcome). Secondary outcomes were established to determine whether:  
1. Pregabalin affects subjective acid pain and discomfort  
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2. Psychological states or traits influence the magnitude of acid-induced VPH pre 
and post Pregabalin 
3. An individual’s autonomic profile at baseline and in response to oesophageal 
acid infusion is associated with the effectiveness of Pregabalin. 
 
 
5.2 PATIENTS AND METHODS 
 
5.2.1 Study design 
A prospective, double-blinded, placebo-controlled, cross-over study was conducted 
over three visits (CONSORT
233 234
 
235
diagram: Figure 5.2). Volunteers who sensitised 
to acid at the screening visit were included in subsequent studies. After visit 1, eligible 
volunteers were randomised (performed by the Barts and the London NHS Trust 
pharmacy using a computer-generated randomisation schedule) and given medications 
with written instructions. Visits 2 and 3 were undertaken after completing the course 
of medication.  
 
5.2.2 Pregabalin dosing 
Based on the results of previous studies
236
 
237
, Pregabalin (Pfizer, Kent, UK) was self-
administered 75 mg twice daily for three days, 150mg twice daily on the fourth day 
and 150mg in the morning of the  return visit on the fifth day (12 x 75mg capsules 
total provided in a single bottle). Medications and instructions were given at the end of 
visits 1 and 2. The interval between visit 1 (screening visit) and visit 2 was at least 
seven days, as retrospective analysis of departmental data has shown sensitisation is 
reproducible within one week. However, the interval between visits 2 and 3 was at 
least two weeks to allow time for the complete washout of Pregabalin. Volunteers 
were asked to return the medication bottle on subsequent visits. 
 
5.2.3 Subjects 
Adult healthy volunteers, aged 18 to 60, were recruited by advertisement. All had 
normal medical assessments including a detailed medical interview, and none was 
taking any regular medication. Urine tests were performed at all visits to exclude 
pregnancy (First Step FS208 Euromed Limited, UK) and drugs of abuse (Triage 8 
TM, Biosite San Diego USA). An oesophageal manometry was carried out on each 
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subject at the screening visit to exclude motility disorders and to locate the lower 
oesophageal sphincter (LOS). Written informed consent was obtained from the 
participants after the nature and the purpose of the trial had been explained. The 
protocol was approved by the local ethics committee (Research ethics committee 
reference: 07/MRE08/39 and MHRA (Medicine and Healthcare products Regulatory 
Agency). Details of the ethical application and MHRA are set out in Appendix 5.01-
5.02. 
 
5.2.4 Intubation and set-up 
All experiments were conducted with subjects seated on a couch, having fasted for a 
minimum of six hours and usually from the night before. A short medical interview 
was performed during all visits, including general health, and at visits 2 and 3 a short 
interview on side effects and compliance. The catheter and pH probe assembly was 
passed trans-nasally into the oesophagus without local anesthetic. Only water-based 
gel (KY Jelly, Johnson & Johnson) was used to lubricate the catheters. Electrical 
stimulations of the oesophagus and a control area (foot) were performed at four time 
points: baseline prior to acid infusion and 30 minutes and 90 minutes after 30-minute 
continuous acid infusion.  
 
5.2.5 Oesophageal acid infusion 
Hydrochloric acid (HCl; 0.15 mol/L) was infused through a port in the electrical 
stimulation catheter (Gaeltec, Isle of Skye, UK), sited 3 cm above the lower 
oesophageal sphincter (LES) at a constant rate of 8 ml/min for 30 minutes via an 
infusion pump (Graseby Medical, Hertfordshire, UK). Previous studies have indicated 
that this acid concentration induces VPH in the majority of healthy subjects
74
 
88
. A 
twin-channel pH catheter (Synectics Medical, Enfield, UK) measured pH in both the 
proximal oesophagus (at the site of electrical stimulation) and in the distal oesophagus 
(at the site of acid infusion) for the duration of each study.  
 
5.2.6 Electrical stimulation 
Oesophageal electrical stimulation was delivered using a pair of 1cm spaced silver-
silver chloride bipolar ring electrodes (Gaeltec, Isle of Skye, UK), as described in 
detail previously
76 205 206
. To act as a somatic control, pain thresholds to electrical 
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stimulation were determined on the dorsum of the right foot using silver-silver 
chloride electrodes with 2 cm spacing: frequency 0.3 Hz, square wave pulses of 500 
μs duration; intensity 0 - 100 mA (Model DS7, Digitimer Ltd, Welwyn Garden City, 
UK). 
 
5.2.7 Outcomes  
Primary outcome: pain threshold to electrical stimulation was recorded in the proximal 
oesophagus (19 cm above the lower oesophageal sphincter) as the lowest intensity in 
mA at which the subject reported pain to 2 mA stepwise stimulus increments. 
Measurements were taken at baseline, 30 minutes and 90 minutes after the completion 
of acid infusion. An average of three readings was taken for each time point (Figure 
5.1) 
Secondary outcomes  
(1) Visual analogue scale (VAS) ratings of pain and unpleasantness intensity were 
assessed subjectively for acid infusion. A score of 0 was completely without pain or 
unpleasantness, 3= mild, 5= moderate, 7= severe but tolerable, 10= maximum possible 
pain/ unpleasantness.  
(2) Psychological assessments: State and trait anxiety were assessed using the 
Spielberger Trait Anxiety Index (STAI) questionnaire: STAI-S for anxiety state and 
STAI-T for anxiety trait. Both questionnaires were completed at the start of the 
screening visit, with the STAI-S assessed again at each separate visit following drug 
administration, as well as after volunteers were connected to the autonomic equipment 
and had shown stable autonomic recordings. This was prior to intubation and acid 
infusion.  
(3) Autonomic recordings: In all experiments, non-invasive arterial blood pressure, 
pulse, ECG and respiratory rate were continuously monitored. Efferent 
parasympathetic activity was measured by deriving a continuous cardiac vagal tone 
(CVT) index (Neuroscope, MediFit Instruments Ltd, London UK)
238-240
. Sympathetic 
activity was measured using R-R interval data to produce the Cardiac Sympathetic 
Index (CSI) 
241. A modified Einthoven’s lead II electrocardiogram was acquired by the 
Neuroscope using three pre-jelled ECG electrodes (ConMed Cleartrace ECG 
electrodes, ConMed, Swindon UK). Electrode sites were below the lateral aspects of 
the right and left clavicles and the left mid-clavicular line below the left nipple. Blood 
pressure was measured continuously with a Portapress non-invasive blood pressure 
  PhD Thesis 2010 
 
___________________________________________________________________________________ 
 
112 
 
monitor (Finapres Medical Systems, Paasheuvelweg 34a, NL-1105 BJ, Amsterdam 
ZO, Netherlands). Respiration rate was monitored via a transducer placed around the 
lower chest (Smartbelt Braebon Medical Corp, New York, USA). All autonomic 
recordings were acquired continuously during the study period, but separated by 
marking of various time periods in the protocol including the five events: baseline, 
pre-acid electrical stimulation during the entire 30-minute acid infusion, as well as 30 
minutes and 90 minutes post acid electrical stimulations. The mean of three periods, as 
demarcated by the markings for three electrical stimuli for each event point, were used 
for ANS measures during electrical stimulation. During acid infusion the mean of the 
whole 30-minute period was used. 
 
 
Figure 5.1: Protocol for the sequence of events and outcomes during each study visit 
 
5. 2.8 Data Analysis 
Retrospective analysis of data from 57 subjects (aged 20-58 years) confirmed that 
subjects who were successfully recruited into previous studies (sensitised) had average 
PT (proximal oesophagus) changes of -7.4mA (-8.4 to -6.3) at 30 minutes post acid 
infusion. This was maintained for up to 120 minutes 
242
. On the basis of intent to treat, 
and using a more conservative estimate of -6mA, 16 subjects were required to detect 
this difference with 90% power at the 5% significance level. Data on heart rate, R-R 
interval, CVT and mean arterial pressure (MAP) were extracted from the Neuroscope. 
R-R interval data were reformatted for entry into the Cardiac Metric program (CMet) 
243
 for the calculation of the Cardiac Sympathetic Index 
241
. All data were cleaned and 
analysed prior to un-blinding. Outcomes took the form of normal and non-normal 
data, and appropriate parametric and non-parametric data analyses employed using 
proprietary software (GraphPad Software, Inc., California, USA). ‘Column statistics’ 
command weas used to test for the normality of data, median and data spread. As 
5-day 
medication 
 
 
30min 
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outcome data were non-parametric, the Wilcoxon paired test was used to compare 
outcomes for placebo and Pregabalin visits. 
 
 
5.3 RESULTS 
 
5.3.1 Subjects and recruitment  
A total of 21 subjects were recruited (Figure 5.2). Two subjects could not tolerate 
nasal intubation (even though intubations were successful), while a further two 
showed no evidence of oesophageal sensitisation following acid infusion during the 
screening visit and were excluded as per protocol. One subject decided not to continue 
with the study post-randomisation, leaving 16 subjects who completed all three visits. 
All were naïve subjects never previously subjected to this model of acid perfusion. Of 
the 16 subjects who completed the study, one subject was excluded from analysis. 
This volunteer reached maximum pain threshold (100mA) for all stimuli for the 
second and third visits, and thus any difference between the placebo and drug would 
not be detected. Results from a total of 15 subjects were analysed: age 21-56 (median 
31) years, six female.  
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Figure 5.2: CONSORT flow diagram
233-235
 illustrating the progress of volunteers 
through this trial including recruitment, enrollment, randomisation, withdrawal and 
completion. Final analysis: N=15. 
 
5.3.2 Oesophageal acid infusion 
During acid infusion, the pH level fell to < 2 in the distal oesophagus but remained > 6 
in the upper (unexposed) oesophagus. The most common symptom reported with acid 
Screening 
N=21 
Pregabalin 
N=7 
Placebo 
N=10 
(1 decided not to go further 
with intubation) 
Placebo 
N=7 
Visit 1 
Visit 2 
Visit 3 
 
At least 1 week  
At least 2 weeks 
apart 
Pregabalin 
N=9 
Analysis 
N=7 
 
Analysis 
N=8 
(1 excluded due to 
reaching maximum PT) 
 
Completion 
Randomisation 
N=17 
Exclusion 
Non-sensitisers N=2 
Intolerable intubation N=2 
  Y. C. Chua 
 
___________________________________________________________________________________ 
 
 115 
infusion was nausea. Other sensations included a cold sensation in the chest region 
and the feelings of hunger and/or heartburn. 
 
5.3.3 Drug administration and adverse events 
All 15 subjects complied fully with medication instructions. Compliance was 
acceptable based on the number of capsules found in the returned bottles and self-
reporting, while the mean number of capsules remaining per visit (12 in total) were 
placebo (0.47, CI 0.005-0.9) and drug (0.33, CI -0.07 to 0.7). As expected, mild 
drowsiness was the most common side effect reported
244-246
. Euphoria was reported in 
one subject. Dizziness was also reported in two subjects, once after the placebo visit 
and once after the Pregabalin visit. Seven subjects were completely symptom free 
from any symptoms at all visits. 
 
5.3.4 Primary endpoints 
At the screening visit, all subjects demonstrated proximal oesophageal sensitisation 
following distal acidification (as per inclusion criteria). The proportion of sensitisers 
was significantly reduced from 53% to 20% at 30 minutes and 47% to 20% at 90 
minutes after treatment with Pregabalin in comparison to the placebo (Figure 5.3). 
There was no difference in the absolute values of pain thresholds (PT) at baseline in 
subjects after receiving the placebo or Pregabalin (median 36mA (15.3-41.3) vs. 30 
(17.3-48.7), p=0.42). However, Pregabalin prevented the development of acid-induced 
VPH in the proximal oesophagus (Figure 5.3 B). At 30 minutes, the median change in 
PT for all subjects was -10.0mA (-11.3 to +1.3) after treatment with the placebo, 
compared to an increase of +0.70mA (-2.7 to +3.3) after Pregabalin (P = 0.0084). This 
pattern was also observed at 90 minutes: the change in PT was -4.0mA (-10 to +2.0) 
after the placebo and +2.0mA (-4.7 to 7.3) after Pregabalin (P = 0.026). 
 
Control area: Pregabalin had no significant effect on baseline somatic (foot) pain 
compared to the placebo (placebo 38mA (24 to 46) vs. Pregabalin 36.7mA (31 to 73), 
p=0.77). At 30 minutes post acid infusion, there was no significant change in PT 
between the placebo (median 0mA (CI 0 to 3.3)) and Pregabalin (median = 0mA (CI -
2 to 2.7), p=0.36). Likewise, there was no difference at 90 minutes: median change in 
  PhD Thesis 2010 
 
___________________________________________________________________________________ 
 
116 
 
PT = 0mA (CI -7 to 4) after the placebo vs. -1.3mA (CI -4 to 6) after Pregabalin, 
p=0.90.  
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A      B 
Figure 5.3: (A) Percentage of volunteers who developed sensitisation at 30 minutes 
and 90 minutes after the placebo and Pregabalin. (B) Change in PT following acid 
infusion with the placebo and Pregabalin at 30 and 90 minutes. The reduction in PT 
following Pregabalin administration was significantly reduced at 30 and 90 minutes 
in comparison to the  placebo. 
 
 
5.3.5 Secondary endpoints 
 (1) Pregabalin reduced subjective VAS scores for pain and unpleasantness following 
acid infusion: Median VAS was 1 out of 10 for pain for oesophageal acid infusion 
after treatment with Pregabalin compared to 3 out of 10 after treatment with the 
placebo (p=0.027). The median VAS score for unpleasantness during acid infusion 
was unchanged at 5 out of 10 after both Pregabalin and the placebo (p=0.76) (Figure 
5.4).  
 
P= 0.0084 P= 0.026 
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Figure 5.4: VAS scores during acid infusion with placebo and Pregabalin treatment: 
(A) VAS score for pain was lower with Pregabalin in comparison to the placebo, P = 
0.027; (B) VAS score for unpleasantness was similar for the placebo and Pregabalin 
visits, P = 0.76. 
 
(2) Effect of anxiety state and trait: The anxiety state STAI-S scores were almost 
identical for the placebo and Pregabalin visits, with very narrow 25-75 percentile 
ranges (median of 52 (48-53) vs. 51 (50-52) respectively p=0.76). STAI-T did not 
predict the degree of sensitisation with the placebo or Pregabalin at 30 or 90 minutes 
(Linear regression of STAI-T vs. sensitisation: Placebo: 30 mins: r2 = 0.12 (P = 0.19), 
90 mins: r
2
 = 0.001 (P = 0.96); Pregabalin: 30 mins: r2 = 0.22 (P = 0.07), 90 mins r
2
 = 
0.03 (P = 0.54)). 
 
(3) Effect of Pregabalin on autonomic functions: Taking the combined event point 
during each visit, Pregabalin significantly reduced parasympathetic variables (CVT) 
(p=0.0001) but increased sympathetic tone (CSI) in comparison to the placebo 
(p=0.0007). Looking at table 5.1, this reduction in CVT was evident at the baseline for 
Pregabalin in comparison to the placebo (p=0.01). In contrast to the other time points 
of the study, during acid infusion CVT was higher for the Pregabalin visit in 
comparison to the placebo visit (p=0.03); a higher sympathetic tone (CSI) during acid 
infusion was also observed for Pregabalin than for the placebo (p=0.04) 
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 Baseline T0 Acid  T30 T90 
CVT      
Placebo 
6.00 
 (4.54-8.53) 
7.18  
(5.25-10.15) 
6.16  
(4.71-10.33) 
8.36  
(5.53-11.37) 
9.02  
(4.86-9.02) 
Pregabalin 
4.86  
(3.81-8.13) 
5.90  
(4.51-7.92) 
6.59  
(4.78-7.80) 
7.91  
(4.83-10.34) 
7.80  
(5.15-11.90) 
p-value 0.01 0.05 0.03 0.04 0.15 
CSI      
Placebo 
3.08 
 (2.31-3.64) 
2.68  
(2.24-3.48) 
3.09  
(2.26-3.51) 
2.83  
(2.07-3.58) 
2.65  
(1.94-3.60) 
Pregabalin 
3.17  
(2.66-3.77) 
3.50  
(2.63-4.04) 
3.43  
2.92-4.33) 
3.11  
(2.25-4.23) 
3.02  
(2.59-4.18) 
p-value 0.1 0.38 0.04 0.24 0.17 
mBP      
Placebo 
98.90 
(83.40-104.10) 
99.90  
(88.90-106.90) 
114.00 
 (102.10-116.30) 
102.30  
(99.00-106.10) 
100.20  
(93.50-108.60) 
Pregabalin 
98.10  
(83.35-108.40) 
91.50  
(83.15-108.30) 
105.00  
(89.00-113.60) 
102.30  
(98.20-106.50) 
100.60  
(89.15-108.70) 
p-value 0.9 0.76 0.58 0.86 0.95 
HR      
Placebo 
74.10  
(68.00-77.70) 
72.40  
(66.30-80.70) 
76.50  
(67.7-81.30) 
71.30  
(67.30-79.30) 
70.80  
(64.0-78.90) 
Pregabalin 
71.30  
(69.90-77.40) 
72.50  
(70.40-76.10) 
73.00  
(64.70-76.80) 
69.40  
(64.00-76.40) 
67.70  
(62.25-75.15) 
p-value 0.9 0.5 0.15 0.86 0.22 
 
Table 5.1: Median values (with 25
th
 to 75
th
 percentile range) of ANS parameters 
across all time points during the placebo and Pregabalin visits. P values were based 
on the Wilcoxon test. 
 
 
5.4 DISCUSSION 
This randomised crossover study of healthy volunteers who had previously developed 
VPH on acid exposure has shown that, in comparison to placebo, Pregabalin 
prevented the development of VPH to electrical stimulation in the non-exposed 
proximal oesophagus after acid exposure in the distal oesophagus, reduced the 
subjective sensation to acid infusion and lowered the parasympathetic tone, except 
during acid infusion, when the parasympathetic tone was higher. State and trait 
anxiety levels did not influence baseline acid sensitivity or the effects of Pregabalin.  
 
In the current study, the demonstration of the anti-hyperalgesic effect of Pregabalin in 
our acid-induced oesophageal hypersensitivity model suggests a central mechanism of 
action, i.e. a reduction in central sensitisation. This is in keeping with data from 
rodents that suggest that the primary site of action of Pregabalin (and the related 
molecule gabapentin) is central
247 248
. Both drugs are considered to modulate the 
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processing of nociceptive signals at the dorsal horn
249
 
250
, with evidence that both can 
also modulate descending inhibition of pain processing by higher brain centres 
247 248
. 
 
The efficacy of Pregabalin in reducing hyperalgesia in somatic neuropathic pain has 
been extensively demonstrated in chronic pain conditions
226 251 252
 
253
. Similarly, 
evidence is emerging of the antihyperalgesic effects of Pregabalin in animal
254
 and 
human models
232
 of visceral pain. For example, in rodents, Pregabalin has been shown 
to reduce hyperalgesia to colonic rectal distension in the rat following injection with 
bacterial lipopolysaccharide
255
. Furthermore, in a recent preliminary study in patients 
with IBS, Pregabalin reduced rectal hyperalgesia to distension
232
. The distinction 
between the analgesic and anti-hyperalgesic effects of Pregabalin may be dose-related. 
In rodent studies, using injections of either trinitrobenzene sulfonic acid or 
lipopolysaccharide in the colon, the anti-hyperalgesic effects of intra-peritoneal 
Pregabalin were obvious at lower doses
254 255
, but at higher doses analgesic effects 
were also observed
255
. In addition, in studies of patients with chronic neuropathic pain, 
e.g. post-herpetic neuralgia and diabetic peripheral neuropathy, doses up to 600mg per 
day, either in fixed doses or an escalating regime of up to 12 weeks
253 256
, were 
associated with significant improvements in pain. It is thus possible that had higher 
doses of Pregabalin been administered in the current study, or been continued for 
longer, an analgesic effect may have been observed in addition to the anti-
hyperalgesic effects.  
 
While PS and CS are considered to be important mechanisms in VPH, there is also 
increasing evidence that anxiety and stress are important in the development and 
perception of symptoms in GORD patients, particularly in NERD and FH 
257
 sufferers. 
Such effects have been observed in clinical GORD studies as well as human 
experimental studies using functional imaging methods and oesophageal 
stimulation
258 259
. The effect of acute stress is thought to be mediated by specific brain 
areas modulating descending spinal inhibitory and excitatory pathways
259
 (as well as 
HPA and ANS changes)
260-262
. Thus, we aimed to also explore whether the effects of 
Pregabalin were influenced by state or trait anxiety or by changes in autonomic 
functions. The anxiety state and trait questionnaires did not yield any positive 
correlations with the degree of sensitisation and response to Pregabalin. This may be 
because the sample size calculation for this study was based on the number required to 
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achieve a difference in pain thresholds in the two groups. Furthermore, only healthy 
volunteers were recruited, whose scores for STAI-S were uniformly low and therefore 
unlikely to influence sensitisation. It is noteworthy that a recent study of the model 
used has demonstrated that experimentally induced anxiety increases secondary 
hyperalgesia to distal oesophageal acidification
82 220
.  
 
Interpretation of the autonomic data is more complex. The classic fight/flight response 
to stressful events such as acute pain is one of sympathetic activation and 
parasympathetic withdrawal, which was mimicked by acid infusion in the placebo arm 
of our study. Pregabalin modulated this classic ANS response to pain by preventing 
PNS withdrawal, although sympathetic co-activation was also observed. Pregabalin 
has previously been shown in rats to be more effective in sympathetically-maintained 
rather than sympathetically-independent pain
263
. Our findings are therefore consistent 
with Pregabalin being more efficacious in sympathetically dominant states such as 
during acid infusion, perhaps because in such situations the prevention of PNS 
withdrawal is important in reducing pain processing given the established 
antinociceptive role of the PNS. A previous study has confirmed that increased SNS 
and lowered vagal parasympathetic activity were associated with increased sensitivity 
to acid in patients with FH compared to volunteers
264
. We might expect, therefore, that 
Pregabalin would also be effective in sympathetically dominant states including 
highly anxious VPH NERD and FH patients. The co-activation of SNS and PNS 
during acid infusion was also observed in our previous study
265
 of oesophageal pain, 
indicating that SNS activation is not always associated with a reciprocal drop in 
PNS
266
 
267
, but instead a co-activation of PNS is believed to have a compensatory role 
in response to tachycardia
265
 or other physiological changes resulting from SNS 
activation in an attempt to optimise or normalise physiology
266
.  
 
There may be a question as to whether some of the observed ANS changes were 
directly caused by Pregabalin or were the indirect effect of a less painful state after 
treatment. The baseline data (Table 5.1) prior to electrical stimulation demonstrated 
that even at this point, CVT was lower for the Pregabalin in comparison to the 
placebo. Furthermore, baseline electrical thresholds were similar for treatment with 
either the placebo or Pregabalin. Together, this suggests that Pregabalin may lead to 
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primary ANS changes and thence modulate VPH rather than the other way round. On 
the other hand, the cause and effect relationship of Pregabalin on sensation caused by 
the acid infusion was less clear. However, assuming a blunted PNS withdrawal 
response to acid after Pregabalin treatment was responsible for this reduced pain, the 
prevention of PNS withdrawal or promotion of PNS elevation by other 
pharmacological and non-pharmacological means should have the same effects by 
reducing acid-induced pain. These questions are currently being explored by further 
studies. 
 
While we acknowledge that Pregabalin should not be used as a substitute for acid 
suppressant treatment, it may have a role in symptom reduction in patients that have 
previously been sensitised by acid exposure. It has the potential to be used in 
conjunction with an acid suppression treatment. In these patients, if VPH has 
developed from previous acid exposures, even a small amount of acid could trigger 
symptoms in the absence of physical changes or damage detected by endoscopy.  
 
Reliance on the self-administration of capsules inevitably leads to questions of 
compliance; however, this was equal and good for both drug and placebo. Assuming 
the placebo effect is unaltered by the actual dose, the significant treatment effect 
observed would be likely to be even greater had compliance been 100%. Inevitably, in 
most drug studies, placebo effects exist, which is why a placebo controlled design is 
usually necessary. In this study, all subjects included in the study sensitised in the 
screening visit after distal acid infusion, as per our inclusion criteria. However, post 
randomisation, for the placebo visit and Pregabalin visits, the rates of sensitisation 
were 53% and 20%, respectively. Pregabalin seemed to have an effect above placebo 
in reducing sensitisation. Furthermore, the screening visit was always the first visit, 
while the post randomisation placebo and Pregabalin happened on either visits 2 or 3. 
The first visit is often the most anxious visit for naïve volunteers. The observed 
placebo effect in comparison to the screening visit could have been influenced by this 
order effect.  
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5.5 CONCLUSION 
 
In this study, we have shown that in healthy volunteers Pregabalin prevents and 
reduces oesophageal pain hypersensitivity in the oesophagus after distal acidification. 
It has been shown to be effective in relatively small doses and for a short duration of 
treatment. The use of smaller doses is likely to minimise potential side effects; 
however, using larger doses and different regimes could be explored further and 
benefit more refractory patients. We believe Pregabalin may have a role in the 
reduction of symptoms in patients with NERD and FH where VPH is a feature, and a 
‘proof of concept’ study in these patients would be warranted to explore this further.  
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CONCLUSION: TOWARDS COHORT 
DEVELOPMENT, TARGETTED THERAPY AND 
FUTURE DIRECTIONS 
 
 
6.1 SUMMARY OF EXPERIMENTS 
The studies in the previous chapters explored the roles of peripheral sensitisation (PS) 
and central sensitisation (CS) in the context of acid-induced visceral pain 
hypersensitivity (VPH). In this final chapter, the clinical relevance and integration of 
both PS and CS concepts in clinical practice will be discussed, together with new 
developments and limitations of this model.  
 
1. Chapter 2 (Full-thickness oesophageal samples) – Nerve fibres were absent 
within the human oesophageal epithelium. The epithelial acid-sensing ion 
channel (ASIC3) was identified in full-thickness human oesophagus and 
considered a suitable candidate in oesophageal mucosal biopsy samples. 
2. Chapter 3 (Oesophageal biopsies from GORD patients) – Epithelial ASIC3 
morphology and distribution were correlated with symptoms of GORD. The 
three main findings were: i) ASIC3 in the basal layer of the epithelium and its 
perinuclear expression increases from control to NERD and EO; ii) The 
expression of ASIC3 in epithelium is associated with an increase in acid 
complaints, indigestion and sleep problems; iii) NERD/FH patients had the 
most severe symptoms (even more than EO) suggesting superficial epithelial 
biomarkers, including epithelial ASIC3 have important roles in symptoms and 
PS. 
3. Chapter 4 (Reproducibility of human model of VPH) – Acid infusion in the 
distal oesophagus reproducibly reduces the pain threshold (PT) to electrical 
stimulation in the non-exposed proximal oesophagus. This observation is 
maintained from 30 minutes to 120 minutes after acid infusion. Sensitisation is 
noted in up to 70% of the population 
4. Chapter 5 (Pregabalin) – In a prospective, randomised, placebo-controlled, 
double-blinded, cross-over study in healthy volunteers, a 5-day treatment 
6 
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programme with oral Pregabalin reduced and attenuated the drop in PT after 
acid infusion in the proximal oesophagus (CS). Treatment with Pregabalin was 
also associated with the prevention of parasympathetic withdrawal during acid 
infusion. 
 
6.2 FUTURE RESEARCH DIRECTIONS 
The studies and analyses performed answered some questions, but open further issues 
and research ideas. Future direction and work from these studies need to explore 
further issues  
1. Chapter 2 (Full-thickness oesophageal samples) – Some of the difficulties in 
replicating previous work in TRPV1 immuno-staining could result from 
technical variability. Fresh frozen sections could be explored further as nerves 
are less likely to be damaged by formalin fixation. A substitute for the GSK 
antibody, which had proven to be effective needed to be sought. However, by 
not finding a neuronal marker, epithelial receptors and the important role of 
epithelium in the context of PS in the human oesophagus were explored and 
highlighted (Section 2.4.4.1). This area merits further research and is very 
relevant and consistent with emerging evidence. Density and expression of 
epithelial ASIC3 could be an area for future research. 
2. Chapter 3 (Oesophageal biopsies from GORD patients)- Quantitative methods 
are essential, if epithelial ASIC3 density was to be used as an objective 
measure for symptoms in GORD patients (explored in section 3.4.2). Future 
studies recruiting larger number of patients are required to explore this further 
and to  achieve greater statistical significance. 
3. Chapter 4 (Reproducibility of human model of VPH) – Although from 
retrospective analyses the acid infusion model seemed robust, the question of 
reproducibility of the model after multiple acid infusions needed to be 
explored prospectively and systematically. This can be best achieved by a 
study replicating multiple visits (and acid infusion) without a drug or placebo. 
4. Chapter 5 (Pregabalin) –Pregabalin has proven to be efficacious in preventing 
CS in proximal oesophagus after distal oesophageal acidification via 
prevention of cardiac vagal tone (parasympathetic) withdrawal during acid. It 
is worth exploring if a pure autonomic modulating drug such as atropine/ 
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autonomic modulating behaviour (deep breathing, relaxation, cognitive-
behavioural therapy) could influence VPH (Refer section 6.4.3)? These studies 
are currently underway, where I am also a co-researcher. 
 
 
6.3 CLINICAL IMPLICATIONS  
 
6.3.1 Treatment pathway 
Based on the hypotheses and findings from my studies, I propose a potential treatment 
algorithm (Figure 6.1) for GORD patients with symptoms resistant to medical or 
surgical acid suppression.  
 
These patients are a challenge in primary and secondary care. I believe they represent 
a heterogeneous group of patients and therefore the algorithm outlined below will help 
to identify important mechanisms which will allow targeted treatment in homogenous 
groups of patients, where oesophageal VPH is an important mechanism.  
 
6.3.2 Cohort development  
As mentioned in previous chapters, PS and CS are important mechanisms of 
oesophageal VPH; however, many different factors including ANS profiles, stress and 
personality types modulate PS and CS. Nevertheless, in many patients there is likely 
to be one dominant factor which needs to be identified. A useful starting point would 
be identifying the existence of VPH (Figure 6.1), which could be done by pH 
monitoring or the Bernstein acid perfusion test. Patients demonstrating good symptom 
correlation with acid exposure, although acid exposure time might be within normal 
limits, would be classified as FH. In this group, VPH is expected to be high. Patients 
with poor symptom correlation with excessive symptoms and normal acid exposure 
time may still have VPH, so a simple Bernstein test could be performed to confirm 
this hypothesis.  
 
A practical starting point would be to trial Pregabalin treatment. In responders, CS has 
to be important and they may continue on this treatment in the long term if the benefit 
persists. Pregabalin could be important not just as treatment tool, but also as an 
investigative tool. With non-responders, oesophageal mucosal biopsy to detect 
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receptor abnormality could help to identify patients where PS is important. Again, 
although effective PS modulating drugs are currently limited in the market, the 
existence of receptor abnormalities is important in identifying these patients as a 
separate cohort. Those who do not respond to Pregabalin or show receptor 
abnormalities could be referred for tertiary consultation to a neurogastroenterologist. 
In these patients, specific ANS and psychological profiling could be performed and 
specific pharmacological and non-pharmacological treatment used. This would also 
involve a personalised treatment plan.  
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Figure 6.1: A summary to consolidate the main concepts of the proposed treatment 
pathway for patients where VPH is important, i.e. cohort identification, specific 
investigations and targeted treatment. 
 
6.3.3 Targeted therapy 
With cohort development, it may be possible to identify predominant and underlying 
patho-physiological abnormalities in VPH GORD patients who are resistant to acid 
Oesophageal biopsy & 
identification of receptors 
Central sensitisation 
predominant 
Continuation of centrally 
acting drugs  
 
Non-responders 
 
Responders 
 
Investigations for existence of VPH (e.g. pH monitoring, 
Bernstein acid perfusion test) 
VPH positive: Trial treatment with centrally acting agent 
(e.g Pregabalin) 
Abnormal receptors 
GORD symptoms resistant to PPI/ surgical treatment 
VPH negative? 
Alternative 
explanation/ 
diagnosis 
 
ANS/ psychological 
profiling and 
modulation 
Receptor 
modulating agents 
Normal receptors 
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suppression therapy. These patients can then be managed with targeted treatment 
aiming at both PS and CS. These agents are discussed further in 6.3: Future 
developments.  
 
 
6.4 FUTURE DEVELOPMENTS  
Drug studies are currently being conducted to alter different mechanisms for the 
development of VPH. These drugs can be divided into those that work peripherally 
and those that act more centrally.  
 
6.4.1  Peripheral sensitisation modulating drugs 
In the modulation of peripheral sensitisation, the antagonist or agonist of a particular 
candidate receptor is an attractive proposition. The modulation of receptor TRPV1 is 
the most studied to date in the context of VPH and pain in general (somatic and 
visceral) (Table 6.1), so it therefore acts as a good example to illustrate PS modulating 
drugs, although it is by no means the only receptor involved in VPH. 
 
TRPV1 antagonists are believed to act either directly by blocking the channel pore or 
indirectly by blocking the Ca2+ channel
268
. For many years, the only known TRPV1 
antagonist was ruthenium red, which is a general TRPV inhibitor
269
. Capsazepine is 
the newest TRPV1 antagonist, which is more specific than ruthenium red, but using it 
produces its own set of problems. Capsazepine is a relatively weak antagonist
270 271
 
and therefore for it to achieve therapeutic effects, high concentrations are required, 
which can cause it to bind to Ca2+
272
 and acetylcholine receptors
271
. This binding 
causes non-specific anti-cholinergic effects because Capsazepine binds to nicotinic 
acetylcholine receptors
271
. In addition, its effects vary for heat-induced pain versus 
acid-induced pain as well as between species
273
. The latter problem has made the 
translation of efficacy from rodents to humans unpredictable and unreliable. Despite 
these problems, though, currently numerous products and trials using TRPV1 
modulation are in place. These include SB-366791 from GlaxoSmithKline (GSK), 
which is a competitive inhibitor of TRPV1
274
, Abbott laboratories have come out with 
A-425619, a promising TRPV1 antagonist
275
, and Johnson and Johnson have created 
JNJ17203212, another TRPV1 antagonist effective in bone cancer pain
275
.  
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To date, the repertoire of active ligands on the ASIC3 channel has been limited to 
amiloride derivatives, non-steroidal anti-inflammatory drugs and gadolinium
276
. For 
amiloride, trials are mainly at the pre-clinical/animal study stages including an 
amiloride derivative, which is an effective ASIC3 inhibitor
181
 and is efficacious in 
acid-related pain in rodent gastritis models
136
 (Chapter 2). There are now newer 
amiloride
182
 derivatives including amidine
181
. In addition, gadolinium has also been 
shown to bind to ASIC3 and effectively reduce electrophysiological response to low 
pH in rat oocytes
277
. More recently, toxin from a sea anemone was discovered and 
found to be an effective ASIC3 inhibitor, at least in cultured sensory neurons
276
. The 
ASIC3 blocker is important not just in the context of acid-induced VPH, but also low 
pH states such as chronic ischemic pain
278
. 
 
The use of agonists, on the other hand, is expected to hyper-stimulate specific 
receptors, and as a result desensitise them. The mechanism is believed to be related to 
excessive Ca2+ influx, which in the long term can cause terminal nerve 
degeneration
279
. Nerve terminals are able to regenerate, and, in theory, the use of 
TRPV1 agonists should not produce permanent change. There is evidence for the 
ablation of TRPV1 containing neurons by capsaicin injection
54 280 281
, and capsaicin 
has been used clinically to alleviate neurogenic pain in herpes zoster, diabetic and 
HIV peripheral neuropathy
44 282 283
. Intrathecal administration of TRPV1 agonists has 
shown efficacy in reducing pain from osteosarcoma in dogs and reducing sensation to 
thermal stimuli
284
. Intrathecal administration is believed to work more effectively by 
acting on TRPV1 in dorsal root ganglia (DRG) in the spinal cord, but in the context of 
VPH this would constitute modulating CS. There is limited evidence on the use of 
ASIC3 agonists. Mammalian neuropeptides FF (NPFF)
285
 and SF (NPFF)
286
 have 
been known to activate (although they did not bind to) ASIC3, but unfortunately these 
two peptides are still very new and non-specific. 
 
Receptor Mechanism(s) Condition Evidence 
Immunoreactive 
TRPV1 
Increase TRPV1 
immunoreactivity in 
sensory nerves is associated 
Faecal urgency Chan, et al
287
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with increased rectal 
hypersensitivity and faecal 
urgency 
Immunoreactive 
TRPV1  
Increased immunoreactivity 
in sensory neurons in colon 
associated with increased 
pain 
IBS, colonic 
motility 
Akbar et 
al.
109
 
 
Immunoreactive 
TRPV1 
TRPV1 is sensitive to low 
pH, heat and capsaicin. 
These factors tend to 
aggravate symptoms in 
GORD patients 
Erosive 
oesophagitis
3
 
Matthews et 
al.
3
 
Immunoreactive 
TRPV1 
Increase free nerve endings 
in epithelium and papillary 
areas is associated with 
increased acid exposure 
time 
GORD (with 
evidence of 
increased acid 
exposure) 
Bhat et al.
141
 
TRPV1 gene and 
protein 
Increased TRPV1 protein 
and gene in patients with 
NERD and EO, but no 
correlation with acid 
exposure time. Likely to 
cause symptoms 
NERD and EO Guarino et 
al.
288
 
 
Table 6.1: Peripheral receptors studied in the context of ‘human’ VPH 
 
TRPV1 is not the only receptor associated with VPH; rather, it is the most established. 
However, the principles are the same as we find with other receptors, as there are 
many with known associations with VPH and their modulation has proven to be 
effective (Table 6.2). Nevertheless, these receptors often also have physiological 
functions. In one animal study, using the TRPV1 antagonist caused significant 
hyperthermia
289
. ASIC3, as mentioned in Chapter 2, is also involved in mechano-
sensation and motility
48
. These good examples illustrate that while many of these 
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receptors may be associated with pain, they also play an important part in homeostatic 
function modulations, and hence care should be exercised in their modulation 
(discussed further in 6.4: Limitations). 
 
6.4.2 Central sensitisation-modulating drugs 
Central modulating agents include a very wide-ranging group of drugs, namely 
modulators of spinal CS, ANS and stress responses as well as prokinetic agents. In 
particular, the success of the CRF receptor antagonist and alpha-2 receptor agonist 
clonidine has highlighted that symptoms in IBS can be treated by HPA axis and ANS 
modulation. Gabapentin and Pregabalin have also been shown to be effective in 
reducing pain caused by rectal distension, relevant in irritable bowel syndrome (IBS) 
patients
232 290
. The table below is a summary of modulators that have been proven 
effective in different functional gastro-intestinal disorders (FGIDs), their mechanisms 
of action and clinical application.  
 
Drug Mechanism(s) Conditions Evidence 
Corticotrophin- 
releasing factor 
(CRF) Receptor 
antagonist 
Blunting of stress-related, 
anxiety-like behaviour in 
the gut especially colonic 
motility. It improves GI 
motility, visceral perception 
and negative mood 
response to GI stimulation 
Irritable bowel 
syndrome (IBS)  
 
Sagami, et 
al.
291 292
 
Alpha2 Adrenergic 
Agonist (Clonidine) 
It reduces pain perception, 
autonomic function 
reactivity and anxiety. 
Colonic transit not affected 
Diarrhoea 
predominant IBS 
Camilleri, et 
al.
293
 
CCK Antagonist Improves oesophageal 
contraction, inhibit 
gallbladder contractions
294 
295
, improves gastric 
emptying and colonic 
transit
296
 
297
 
IBS, Functional 
dyspepsia 
Varga, et 
al.
295
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NMDA Antagonist 
(Ketamine) 
Inhibition of acid induced 
central sensitisation in 
healthy human volunteers 
76
 
Oesophageal 
hypersensitivity to 
acid 
Willert, et 
al.
75
 
Gabapentin Reduces rectal mechano-
sensation and increases 
rectal compliance 
Diarrhoea 
predominant-IBS  
 
Lee, et al.
290
 
Pregabalin It increases sensory 
distension threshold to 
normal in IBS patients with 
rectal hypersensitivity 
IBS  
 
Houghton, et 
al.
232
 
 
Table 6.2: Some examples of drugs relevant to human clinical conditions related to 
VPH. 
 
 
6.4.3 Non-pharmacological modulation of ANS 
There is general consensus that activation of the sympathetic nervous system is pro-
nociceptive, while activation of the parasympathetic nervous system is anti-
nociceptive. Support for this concept is also available in our study of oesophageal 
VPH, where the efficacy of Pregabalin was associated with a reduction in withdrawal 
of the parasympathetic tone during acid infusion in comparison to the placebo. This 
raises the possibility that the modulation of the ANS may be efficacious in 
hypersensitivity states. While ANS can be effectively modulated by pharmacological 
interventions, the logical question to ask would be whether non-pharmacological 
interventions that modulate the ANS can also be effective in modulating VPH. The 
obvious benefit of non-pharmacological interventions is the avoidance of side effects 
inherent with many drugs. Non-pharmacological measures may include cognitive 
behavioural therapy (CBT), breathing and relaxation exercises, etc. Current and future 
work is continuing within the research group to explore whether CS to oesophageal 
acid infusion can be affected by the non-pharmacological modulation of ANS, 
including by exercise and breathing methods, in which I am involved. 
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6.4.4 Novel VPH modulating agents specific to GORD 
Pharmacological agents used to modulate the PS and CS arms of VPH have been 
better studied in IBS than in functional heartburn and dyspepsia. Although the 
modulators of PS and CS have been discussed above, there are, however, other non-
specific neuromodulators that have some efficacy in VPH seen in GORD. These are 
discussed briefly below.  
 
The selective serotonin re-uptake inhibitor (SSRI) Citalopram has been shown to 
reduce symptoms (heartburn, chest pain and regurgitation) in GORD patients with 
evidence of positive symptom correlation to acid exposure on pH impedance, but only 
with normal acid exposure time, suggesting that they are hypersensitive to 
physiological amounts of acid reflux
298
. Symptoms as defined above were reported in 
23% vs. 67% (p=0.047) of patients taking Citalopram or a placebo for six months, 
respectively. A major criticism of this study was that assessments of anxiety and 
depression levels were not performed. The question remains as to whether Citalopram 
reduces symptom reporting by direct analgesic effect or indirectly by its anxiolytic 
and antidepressant effects.  
 
My own Pregabalin study is now ready to move to proof of concept in GORD 
patients. This study demonstrated that a reduction of CS is associated with changes in 
autonomic nervous system (ANS). A clear relationship between ANS and VPH was 
discussed in Chapters 1 and 2.          
                                                          
 
6.5 CONCLUDING REMARKS 
The VPH concept is very much in line with the theory of evolution. Within VPH 
exists great variability between individuals and past experience, so it is not hard to 
imagine survival benefits from VPH in our distant past. Ingesting highly acidic or 
noxious chemicals can cause death, so the ability of the body (the viscera) to recognise 
this at a subconscious level is necessary to avoid future contact with the same 
substance. Interaction with the ANS further consolidates that VPH is linked intricately 
to survival instincts. In times of high stress and danger, the human body is hyper 
vigilant to potential dangers and subsequently lowers perception thresholds. However, 
human lifestyles and experience are constantly changing. Eating in modern life, while 
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still necessary for human existence, has evolved into a high art; it covers social, 
cultural and pleasure roles in equal measure. Foods are highly processed, cooked and 
generally safe and free from contamination from soil and dirt. The role of VPH in 
survival has somehow eroded. The nature of stress has also evolved from running 
away from predators and hunting for food to one of meeting a deadline in an office or 
passing an important viva examination. However, the human evolutionary process is a 
dynamic process – as the environment changes, the human adapts.  
 
One final point of importance in human evolution is the existence of great variability 
between individuals, which promotes a rich diversity of properties within the human 
gene pool. VPH is within the spectrum of human variability, as pain is, after all, a 
subjective experience. At what point is sensation considered to be unpleasant? Is the 
elimination of bodily sensation necessarily always good? Should we remove the 
offending stimuli or sensation? Pain and interpretation are ultimately a result of the 
interaction of past experience, cognitive processes, emotion and the essential 
ingredients of being alive. As we age, most of our sensations numb and we yearn for 
the youthful days when all sensations, including pain, were once so acute, precise and 
exciting!  
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APPENDICES 
 
Chapter 2 
 
 
2.01 NATIONAL RESEARCH ETHICS APPROVAL PROCESS 
The ethical application and approval for both parts of the experiments were made in a 
single application.  
Application 
The application was made via the electronic National Research Ethics Committee 
(NREC) application form, together with all the attachments. This was submitted to the 
committee below.  
Committee 
The ethics application was submitted to the East London and the City Research Ethics 
Committee 3, competent to consider studies involving human tissues. The committee 
was chaired by Dr David Ingram and a panel of other clinicians, lay members and 
administrators.  
The Interview 
The committee met on 19
th
 July 2007 to consider our application. The outcome was 
one of provisional approval subject to some recommended changes. The scientific 
justification and overall structure of all the studies remained intact. The main 
recommended point was to make the risks of serious injuries from gastroscopy more 
explicit to patients and volunteers taking part in the biopsy study (Chapter 5). The 
current accepted risk is quoted as 1/10,000 per gastroscopy. In addition, the patients 
recruited would have the gastroscopy done anyway, thus the scope itself was not for 
research, but rather for the procurement of the biopsy samples. 
Approval 
The recommended changes were made and submitted for consideration by the chair, 
Dr Ingram. Several draft changes were made, but everything was finally approved on 
27
th
 November 2007. The approval reference number is 07/H0705/67 
R&D 
The study was sponsored by the Bart’s and the London NHS Trust, with the R&D 
office as the official sponsor body. As a result, this study also obtained Department of 
  PhD Thesis 2010 
 
___________________________________________________________________________________ 
 
136 
 
Health funding.  
 
Registration of trial website 
To remain compliant, accrual data for the study were constantly updated on the 
National Institute for Health Research (NIHR) via the UKCRN (UK Clinical Research 
Network) website, which also enables UKCRN to fund the Trust appropriately for 
costs incurred by the NHS. The accruals of this study were regularly updated with 
UKCRN. The other benefit included allowing the participants to verify independently 
the legitimacy of the research in which they were involved.  
 
 
2.02 SOLUTIONS AND REAGENTS 
All solutions and reagents were supplied by VWR International, Lutterworth, 
Leicestershire, UK, Dako, Ely, Cambridgeshire, UK (Dako), Bio-Genex Laboratories, 
San Ramon, CA, USA (Bio-Genex). The Vectastain Universal Elite ABC kit and 
R.T.U. Vectastain Universal Elite were supplied by Vector Laboratories Inc., 
Burlingame, CA, USA (Vector), IMS = 100% industrial methylated spirits were 
prepared in-house. 
 
Generic solutions 
Endogenous peroxidase blocking  6ml H2O2 
solution    194ml dH2O 
 
Acid Alcohol    300ml dH2O 
     700ml IMS 
10ml conc. HCL 
(added to 990ml of the above) 
 
Heamatoxylin and Eosin 
Gill’s Haematoxylin   1L dH2O 
     625ml ethylene glycol, 
     10g haematoxylin 
     1g sodium iodate 
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     176g aluminium sulphate 
     50ml glacial acetic acid 
     825ml dH2O 
 
1% Eosin    1g eosin Y 
 
     100ml dH2O 
 
Immunohistochemistry 
Endogenous peroxidase  3ml 30% H2O2 
block (3%)     97ml 100% methanol 
 
REAL™ Antibody diluent (DAKO)  
 
Wash buffer (DAKO)   0.05mol/L Tris HCl 
     0.15mol/L NaCl 
     0.05% Tween 20 
 
Vectastain Universal Elite ABC reagents or 
RTU Vectastain Universal Elite reagents (Vector labs) 
 
Diaminobenzidine    1ml substrate buffer   
tetrachloride (DAB) solution   1 drop DAB chromagen   
(Bio-Genex) 
 
Phosphate buffered saline (PBS)  
Mounting medium for immunohistochemistry: Canada balsam  
 
Antigen retrieval 
Citrate buffer solution (Vector) Citrate buffer stock 100ml  
dH2O 900ml 
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2.03 FIXATION AND PREPARATION OF TISSUES 
1. Fix tissues with 10% formalin or other fixatives for 24-48 hours at room 
temperature. 
2. Fixative volume should be 5-10 times tissue volume. 
3. Trim fixed tissues into appropriate size, shape and place in embedding 
cassettes. 
4. The process for the paraffin embedding schedule is as follows – in most 
modern laboratories, including in our department, this is automated and 
machine operated (Shandon Excelsier ES, ThermoFisher Scientific, 
Leicestershire, UK): 
 Formalin 1 hour and 30 minutes 
 Alcohol (ethanol), six changes, 1 hour each 
 Toluene (Xylene substitute,) three changes, 1 hour each 
 Paraffin wax, three changes, 1 hour and 20 minutes each 
 Embedding tissues into paraffin blocks 
 
5. Trim paraffin blocks as necessary and cut at 3-10 um (5 um is commonly 
used). 
6. Place paraffin ribbon in water bath at about 40-45 ºC. 
7. Pick up sections on negatively charged microscope slides (VWR International, 
Leicestershire, UK) and allow water to drain off. 
8. Dry sections overnight at 37 ºC. 
 
 
2.04 HAEMATOXYLIN AND EOSIN STAINING 
1. Dewax sections in xylene (2x 2 min) 
2. Remove xylene with IMS (2x 2 min) 
3. Wash in running tap water for 5 min 
4. Stain in Gill’s haematoxylin for 20 min 
5. Wash in running tap water for 5 min 
6. Differentiate by dipping in 1 % acid alcohol 
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7. Wash in running tap water for 5 min 
8. Stain in eosin for 3 min 
9. Dip in tap water and blot 
10. Dehydrate rapidly in IMS (2x 2 min) 
11. Clear in xylene (2x 2 min) 
12. Mount in Canada balsam 
 
 
2.05 INDIRECT IMMUNOHISTOCHEMISTRY 
ABC kit (Vectastain Universal Elite ABC: PK-6200) 
1. De-wax sections in Xylene (2 X 2 minutes)  
2. Dehydrate sections in alcohol (2 X 2 minutes) 
3. Place sections in endogenous peroxidase block for 15 minutes (97ml 
methanol, 3ml hydrogen peroxide) 
4. Wash sections in tap water for 2 minutes 
5. If antigen retrieval is required, go to the procedure below (25 minutes 
microwave) 
6. Transfer to tap water and wash for 2 minutes 
7. Soak sections in a trough of wash buffer for 3 minutes 
8. Wipe around the sections and apply the PAP pen (ImmEdge pen, Vector labs) 
9. Apply normal horse serum for 5 minutes 
10. Tip off the horse serum 
11. Apply primary antibody at the appropriate dilution in antibody diluent 
(Dakocytomation) for 40 minutes 
12. Wash off the antibody with wash buffer (twice) and flick the slide to remove 
excess 
13. Apply the Universal Biotinylated secondary antibody (secondary antibody 
from the kit) for 30 minutes. (Add 2 drops of normal horse serum to 5ml of 
wash buffer, and then add 2 drops of biotinylated secondary antibody. Vortex 
this solution) 
14. Make up the Avidin complex solution. This must stand for 30 minutes before 
use. (Add 2 drops of reagent A to 5ml of wash buffer, and then add 2 drops of 
reagent B. Vortex solution. Leave to stand 30 minutes, and drop for 30 
minutes) 
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15. Wash off the antibody with wash buffer (twice) and flick the slide to remove 
excess 
16. Apply the Avidin complex solution for 30 minutes 
17. Wash off with wash buffer X2 and flick the slide to remove excess 
18. Apply the appropriate DAB solution (DAB capsule in distilled water) 
19. Wash in running tap water for 5 minutes 
20. Counter-stain in Gill’s haematoxylin for 2 minutes 
21. Blue in running tap water for 5 minutes 
22. Differentiate in 1% acid alcohol for 2 seconds (appropriately 2 dips) if 
necessary 
23. Wash in running tap water for 5 minutes 
24. Dehydrate, clear and mount 
 
RTU kit (R.T.U. Vectastain Universal Elite) 
1. Place the sections into a plastic staining rack 
2. Dewax sections in Xylene for two changes of 2 minutes each 
3. Remove the Xylene in Alcohol for two changes of 2 minutes each 
4. Place the sections into the sink and wash in tap water for 5 minutes 
If antigen retrieval is required, refer to the appropriate optimisation schedule 
specific to each antibody 
5. If required, carry out Avidin/biotin block (Avidin (Bottle A in Kit ) for 15 
minutes, wash with buffer and Biotin (bottle B in kit) for 15 minutes) 
6. Prepare the 3% endogenous peroxidase (10ml distilled water, 300microlitres 
of hydrogen peroxide)  
7. 3% endogenous peroxidase for 15 minutes 
8. Remove the rack, place in sink and wash in tap water for 5 minutes 
9. Wash out the black plastic staining with distilled water and wash buffer 
10.  Soak wash buffer for 5 minutes 
11. Prepare an immuno-staining tray by adding a few drops of wash buffer to 
create a moist chamber 
12. Taking each slide in turn, wipe around the section to remove excess wash 
buffer, and then using a PAP pen draw a line across the slide above and below 
the section 
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13. Place the section onto the rack in the immuno staining tray and cover with 
wash buffer. Do not allow the sections to dry out 
14. When all of the sections are on the rack, tip off the wash buffer 
15. Apply sufficient drops of normal blocking serum, Normal horse serum, 
(yellow bottle from RTU kit) to cover each section 
16. Put on the lid of the immuno staining tray and leave for 20 minutes 
17. Prepare the primary antibody at the appropriate dilution using antibody diluent 
18. Tip off the normal horse serum 
19. Apply the primary antibody to each test section and the positive control 
section 
20. Apply antibody diluent alone to the negative control section 
21. Replace the immuno staining lid and leave for 40 minutes 
22. Rinse off the primary antibody with wash buffer 
23. Cover each section with wash buffer, replace the immuno staining tray lid and 
leave for 2 minutes. Rinse with wash buffer, cover each section again and 
leave for a further 2 minutes 
24. Tip off the wash buffer 
25. Apply sufficient drops of Universal Biotinylated secondary antibody (Blue 
bottle from RTU kit) to cover each section 
26. Replace the immuno staining tray lid and leave for 30 minutes 
27. Rinse off the secondary antibody with wash buffer 
28. Cover each section with wash buffer, replace the immuno staining tray lid and 
leave for 2 minutes. Rinse with wash buffer, cover each section again and 
leave for a further 2 minutes 
29. Tip off the wash buffer 
30. Apply sufficient drops of the Vectastain Elite Avidin Biotin Complex 
Reagent (Grey bottle from RTU kit) to cover each section 
31. Replace the immuno staining tray lid and leave for 30 minutes 
32. Rinse off the ABC reagent with wash buffer 
33. Cover each section with wash buffer, replace the immuno staining tray lid and 
leave for 2 minutes. Rinse with the wash buffer, cover each section again and 
leave for a further 2 minutes 
34. Into a yellow-topped tube place 1ml of substrate buffer from the Biogenex 
Two Component DAB kit 
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35. To this add 1 drop of the DAB chromogen from the kit and mix well 
36. Tip off the wash buffer from the slides and apply the DAB solution to each of 
the slides for 5 minutes 
37. Wash the slides in tap water for 5 minutes 
38. Load the slides into a machine staining rack ensuring that all of the sections 
are facing in the direction of the arrow on the rack 
39. The remainder of the technique is carried out using machines and involves 
staining the sections with the dye haematoxylin. This stains the nuclei a light 
blue colour, which contrasts against the brown immunocytochemical staining. 
The sections are then dehydrated in alcohol to remove water and washed in 
Xylene before having a glass cover-slip placed over the section to protect it 
and to produce a permanent preparation.  
 
2.06 ANTIGEN RETRIEVAL 
1. Place sections into a plastic staining rack, leaving a gap between the slides 
2. Place the rack into a large glass staining trough containing exactly 1000ml of 
the antigen retrieval buffer 
3. Cover the trough with cling film and make several holes in the cling film 
4. Place the trough in the microwave and run at full power for 25 minutes (for the 
Step kit, this step is always the same and fixed for 25 minutes. This varies with 
the Dako kit, timing and microwave setting specific to the individual 
optimisation schedule) 
5. With care, remove the trough from the microwave 
6. Carefully remove the cling film 
7. Leave sections to stand in the hot buffer for 5 minutes 
8. Return to the original technique 
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2.07 ADDITIONAL TRPV1 VALIDATION  
 
Human colon TRPV1 immunohistochemistry (IHC) staining and immunoblotting with 
the TRPV1 antibody (ThermoFisher). C&D) human colonic TRPV1, E) Human DRG 
with small neurons staining F) Bands in Western blotting. This band on the 
immunoblot could not be repeated with a subsequent batch of antibody intended for 
the oesophagus (Courtesy of Dr George Boundouki) 
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Chapter 3 
 
3.01 ReQuest
TM
 QUESTIONNAIRE  
 
 
3.02 VISUAL ANALOGUE SCALE FOR MULTI-MODAL STIMULI 
Milestones of VAS (scale of 0-10) 
0- No perception 
1- Vague perception* (first sensation) 
2- Definite perception of mild sensation 
3- Vague perception of moderate sensation 
4- Definite perception of moderate sensation 
5- Pain threshold 
6- Mild pain 
7- Moderate pain* (need to stop)*-* 
8- Pain of medium intensity 
9- Intense pain 
10- Unbearable pain 
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3.03 WESTERN BLOTTING OF ABCAM ASIC3 ANTIBODY  
 
 
 
Western blotting performed on ASIC3 antibody (Ab 49333) to validate the specificity 
of this antibody by the manufacturer. It is recommended for use in 
immunohistochemistry in human paraffin fixed samples (c/o: Abcam) 
 
ASIC3 antibody (ab49333) at 2.5 µg/ml + Jurkat cell lysate at 10 µg 
Secondary Antibody: HRP conjugated anti-Rabbit IgG at 1/50000 dilution 
Predicted band size: 59 kDa 
Observed band size: 59 kDa 
Gel concentration 12% 
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Chapter 5 
 
5.01 NATIONAL RESEARCH ETHICAL APPROVAL PROCESS 
Application 
The application was made via electronic the National Research Ethics Committee 
(NREC) application form, together with all the attachments. This was submitted to the 
committee below.  
Committee 
The ethics application was submitted to the North West 5 Research Ethics Committee, 
competent to consider studies involving drug trial. The committee is recognised by the 
United Kingdom Ethics Committee Authority under the Medicines for Human Use 
(Clinical Trials) Regulations 2004 and is authorised to carry out the ethical review of 
clinical trials of medicinal products. The committee was chaired by Dr Donal 
Manning, Vice-chair Dr J Pearson, statistician Mr R Swindell, a panel of other 
clinicians, lay members and administrators. The site specific assessment (SSA) was 
assessed by East London & The City Research Ethics Committee 3 for Barts and the 
London site. 
The Interview 
The ethics application was submitted for consideration on 15
th
 May 2007. The 
outcome was one of provisional approval subject to some recommended changes. The 
scientific justification and overall structure of all the studies remained intact. 
Statistical clarification, consolidation of the volunteer information sheet and a mention 
of Pfizer Ltd in the information sheet were required.  
Approval 
With the changes made, on 4th July 2007 final approval was given. The approval 
reference number is 07/MRE08/39. This study also required a separate approval by 
Medicine and Health Regulatory Agency (MHRA). 
R&D 
The study is sponsored by the Joint Research & Development Office, Barts and the 
London NHS Trust as the official sponsor body.  
Registration of the trial website 
The R&D office and Department of Health recommended registering the trial with 
Current Controlled Trials (CCT) Ltd on their website called ‘ISRCTN’. This study 
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registration can be checked at www.controlled-trials.com/ISRCTN40924266. 
 
5.02 MEDICINE AND HEALTH REGULATORY AGENCY (MHRA) 
Details for the MHRA are EudraCT number: 2006-000499-33, MHRA number: 
21313/0026/001, Protocol number: 2006neuro06. Final MHRA approval was obtained 
on 4
th
 May 2007. Documents for audits and inspections were updated during the study 
period. Annual safety reports were made and this study was closed with MHRA on 
16
th
 April 2010. 
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